BE2016C059I2 - - Google Patents

Download PDF

Info

Publication number
BE2016C059I2
BE2016C059I2 BE2016C059C BE2016C059C BE2016C059I2 BE 2016C059 I2 BE2016C059 I2 BE 2016C059I2 BE 2016C059 C BE2016C059 C BE 2016C059C BE 2016C059 C BE2016C059 C BE 2016C059C BE 2016C059 I2 BE2016C059 I2 BE 2016C059I2
Authority
BE
Belgium
Application number
BE2016C059C
Other languages
Dutch (nl)
Original Assignee
Novozymes Biopharma Dk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27394014&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2016C059(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novozymes Biopharma Dk As filed Critical Novozymes Biopharma Dk As
Publication of BE2016C059I2 publication Critical patent/BE2016C059I2/nl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4846Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38Albumins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/12Keratolytics, e.g. wart or anti-corn preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • A61P33/12Schistosomicides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • C07K14/56IFN-alpha
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/61Growth hormone [GH], i.e. somatotropin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/65Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76Albumins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76Albumins
    • C07K14/765Serum albumin, e.g. HSA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/50Fusion polypeptide containing protease site
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
BE2016C059C 2000-04-12 2016-11-04 BE2016C059I2 (h)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US22935800P 2000-04-12 2000-04-12
US19938400P 2000-04-25 2000-04-25
US25693100P 2000-12-21 2000-12-21
EP06076852A EP1832599A3 (en) 2000-04-12 2001-04-12 Albumin fusion proteins
EP08075909A EP2067488A1 (en) 2000-04-12 2001-04-12 Albumin fusion proteins
EP01934875A EP1278767A4 (en) 2000-04-12 2001-04-12 ALBUMIN FUSED PROTEINS

Publications (1)

Publication Number Publication Date
BE2016C059I2 true BE2016C059I2 (h) 2020-08-20

Family

ID=27394014

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2016C059C BE2016C059I2 (h) 2000-04-12 2016-11-04

Country Status (10)

Country Link
US (23) US6905688B2 (h)
EP (21) EP2213743A1 (h)
JP (9) JP2004506407A (h)
AU (7) AU2001264563A1 (h)
BE (1) BE2016C059I2 (h)
CA (8) CA2405525A1 (h)
DK (2) DK2236152T3 (h)
ES (2) ES2484966T3 (h)
FR (1) FR16C0043I2 (h)
WO (7) WO2001079480A1 (h)

Families Citing this family (666)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
WO2002016388A1 (en) * 2000-08-18 2002-02-28 Human Genome Sciences, Inc. 21 human secreted proteins
WO2001034626A1 (en) * 1999-11-05 2001-05-17 Human Genome Sciences, Inc. 28 human secreted proteins
US20020137890A1 (en) 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP0892047A3 (de) * 1997-07-09 2000-03-08 Hoechst Marion Roussel Deutschland GmbH Humanes und murines Semaphorin L
US20030166106A1 (en) * 1997-09-18 2003-09-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6548653B1 (en) * 1998-06-15 2003-04-15 Genzyme Transgenics Corporation Erythropoietin analog-human serum albumin fusion
US20050181482A1 (en) * 2004-02-12 2005-08-18 Meade Harry M. Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
US20040199099A1 (en) * 1998-07-10 2004-10-07 Matson James R Hemofiltration systems, methods and devices used to treat inflammatory mediator related disease
US20030190740A1 (en) 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
JP2002534059A (ja) 1998-10-13 2002-10-15 ザ ユニバーシティ オブ ジョージア リサーチファウンデーション,インコーポレイティド 安定化された生物活性ペプチドおよび同定、合成および使用方法
DE60026695T2 (de) * 1999-05-05 2006-11-02 Phylogica Ltd., Northbridge ISOLIERUNG VON BIOLOGISCHEN MODULATOREN AUS BIBIOTHEKEN MIT BIOLOGISCH VIELFäLTIGEN GENFRAGMENTEN
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US7632803B2 (en) 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US7592304B2 (en) 1999-10-01 2009-09-22 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
JP2003528587A (ja) * 1999-10-29 2003-09-30 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド 27個のヒト分泌タンパク質
EP1235845A4 (en) * 1999-11-05 2003-06-25 Human Genome Sciences Inc 24 HUMAN SECRETED PROTEINS
JP2003520031A (ja) * 1999-11-12 2003-07-02 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド 28個のヒト分泌タンパク質
WO2001039722A2 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
DE60041564D1 (de) 1999-12-24 2009-03-26 Genentech Inc Verfahren und Zusammensetzungen zur Verlängerung der Entsorgungshalbwertszeit von biowirksamen Verbindungen
US7534417B2 (en) 2000-02-24 2009-05-19 Agensys, Inc. 103P2D6: tissue specific protein highly expressed in various cancers
US7291122B2 (en) * 2000-03-24 2007-11-06 Immunocept, L.L.C. Hemofiltration methods for treatment of diseases in a mammal
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
EP2213743A1 (en) * 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
US7030219B2 (en) * 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
WO2001085936A1 (en) * 2000-05-12 2001-11-15 Merck Patent Gmbh F-box containing protein
US6787040B2 (en) * 2000-05-16 2004-09-07 Immunocept, L.L.C. Method and system for colloid exchange therapy
AU2001274923A1 (en) * 2000-05-23 2001-12-03 Lexicon Genetics Incorporated Novel human thrombospondin-like proteins and polynucleotides encoding the same
US6965018B2 (en) 2000-06-06 2005-11-15 Bristol-Myers Squibb Company Antibodies directed to B7-related polypeptide, BSL-2
JP2004500862A (ja) * 2000-06-08 2004-01-15 インサイト・ゲノミックス・インコーポレイテッド 細胞内シグナル伝達タンパク質
AU2001219323A1 (en) * 2000-06-21 2002-01-02 Amgen Inc. Secreted epithelial colon stromal-1 polypeptides, nucleic acids encoding the same and uses thereof
AU2001229509A1 (en) * 2000-08-18 2002-03-04 Human Genome Sciences, Inc. 11 human secreted proteins
AU2001232810A1 (en) * 2000-08-18 2002-03-04 Human Genome Sciences, Inc. 23 human secreted proteins
AU2001232835A1 (en) * 2000-08-28 2002-03-13 Human Genome Sciences, Inc. 18 human secreted proteins
CA2420192A1 (en) * 2000-09-20 2002-03-28 Human Genome Sciences, Inc. 21 human secreted proteins
AU2001227920A1 (en) * 2000-09-29 2002-04-15 Human Genome Sciences, Inc. 24 human secreted proteins
EP1325120A4 (en) * 2000-10-12 2005-05-25 Nuvelo Inc NUCLEIC ACIDS AND POLYPEPTIDES
US6531297B2 (en) * 2000-10-20 2003-03-11 Applera Corporation Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
US6949371B2 (en) 2000-10-20 2005-09-27 Applera Corporation Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
FR2815964A1 (fr) * 2000-10-30 2002-05-03 Inst Nat Sante Rech Med Proteine recepteur de la renine et/ou de la prorenine, acide nucleique codant pour ce recepteur et leur applications
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
DE60128008T2 (de) * 2000-12-05 2008-01-10 Wisconsin Alumni Research Foundation, Madison Rezeptor für ein toxin aus bacillus anthracis
CN1483041A (zh) 2000-12-07 2004-03-17 Glp-1融合蛋白
US20030148920A1 (en) * 2000-12-27 2003-08-07 Steven Rosen Sulfatases and methods of use thereof
EP1354950A4 (en) * 2000-12-28 2005-01-12 Asahi Kasei Pharma Corp ACTIVATION GENE OF NF-KB
EP1368468A4 (en) * 2001-02-23 2005-02-16 Human Genome Sciences Inc 83 HUMAN SECRETED PROTEINS
EP1365801A4 (en) * 2001-03-08 2004-10-13 Nuvelo Inc METHODS AND MATERIALS RELATING TO FIBULIN-RELATED POLYPEPTIDES AND POLYNUCLEOTIDES
WO2002083921A2 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
US7507413B2 (en) * 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20050244931A1 (en) * 2001-04-12 2005-11-03 Human Genome Sciences, Inc. Albumin fusion proteins
US20060084794A1 (en) * 2001-04-12 2006-04-20 Human Genome Sciences, Inc. Albumin fusion proteins
US7250495B2 (en) 2001-06-20 2007-07-31 Genentech, Inc. PRO20044 polypeptides
AU2002328853A1 (en) * 2001-07-06 2003-01-21 Geneprot, Inc. Carcinoma-related peptides
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
AU2002332041A1 (en) * 2001-10-05 2003-04-22 Human Genome Sciences, Inc. Albumin fusion proteins
DE10251673A1 (de) 2001-11-09 2003-07-10 Hoffmann La Roche Alström-Syndrom-Gen, Genvarianten, codiertes Protein und Verfahren zur Diagnose des Alström-Syndroms
KR100406760B1 (ko) * 2001-11-16 2003-11-21 신코엠 주식회사 반도체 메모리 장치
ES2320743T3 (es) 2001-12-17 2009-05-28 Laboratoires Serono Sa Mutantes de quimiocina que actuan como antagonistas de quimiocinas.
US20040082761A1 (en) * 2001-12-18 2004-04-29 Duggan Brendan M. Cell adhesion proteins
EP1463752A4 (en) * 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
KR101271635B1 (ko) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
US20060253913A1 (en) * 2001-12-21 2006-11-09 Yue-Jin Huang Production of hSA-linked butyrylcholinesterases in transgenic mammals
CA2841097A1 (en) * 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
US20080194481A1 (en) * 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
US7081446B2 (en) * 2002-01-31 2006-07-25 The Trustees Of Columbia University In The City Of New York Long-acting follicle stimulating hormone analogues and uses thereof
CN1642567A (zh) * 2002-02-07 2005-07-20 达尔塔生物技术有限公司 Hiv抑制蛋白
US20060241027A1 (en) * 2002-02-07 2006-10-26 Hans-Peter Hauser Hiv inhibiting proteins
US20050222023A1 (en) * 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
DE10205520A1 (de) * 2002-02-08 2003-08-14 Aventis Behring Gmbh Inhibitorischer, monoklonaler Antikörper gegen die den Blutgerinnungsfaktor VII aktivierende Protease
MXPA04008149A (es) * 2002-02-21 2005-06-17 Wyeth Corp Proteinas que contienen dominios de folistatina.
CA2477614A1 (en) * 2002-03-05 2003-09-18 Merck & Co., Inc. Biomarker for efficacy of appetite suppressant drugs
US20030191056A1 (en) * 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
US20070015230A1 (en) * 2002-04-15 2007-01-18 Hammond David J Identification and characterization of analytes from whole blood
US7223734B2 (en) * 2002-04-15 2007-05-29 The American National Red Cross Plasma protein-binding ligands
WO2003089608A2 (en) 2002-04-18 2003-10-30 The General Hospital Corporation Drg11-responsive (dragon) gene family
US7141381B2 (en) 2002-04-25 2006-11-28 Bristol-Myers Squibb Company Human leucine-rich repeat-containing proteins specifically expressed in the nervous system
GB0210464D0 (en) * 2002-05-08 2002-06-12 Svanborg Catharina Therapeutic treatment
JP2006514601A (ja) * 2002-06-07 2006-05-11 ザイモジェネティクス インコーポレイティッド ガンおよびその他の治療用途におけるil−21の使用方法
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
ATE477020T1 (de) 2002-06-07 2010-08-15 Dyax Corp Prevention und verringerung von ischemia
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US8029803B2 (en) 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
CN1241946C (zh) * 2002-07-01 2006-02-15 美国福源集团 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
CN101172091B (zh) * 2007-09-25 2011-04-27 北京美福源生物医药科技有限公司 含人血清白蛋白与皮肤细胞生长因子的融合蛋白护肤产品制备工艺和用途
AU2003245090A1 (en) * 2002-07-03 2004-01-23 Nexgen Biotechnologies, Inc. Method for preparing fusion polypeptide comprising epidermal growth factor and human serum albumin in plants
WO2004004649A2 (en) * 2002-07-08 2004-01-15 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CA2493263A1 (en) * 2002-07-22 2004-01-29 Yamanouchi Pharmaceutical Co., Ltd. Novel gene associated with rheumatoid arthritis
GB0217033D0 (en) 2002-07-23 2002-08-28 Delta Biotechnology Ltd Gene and polypeptide sequences
JP2005534330A (ja) * 2002-08-07 2005-11-17 デルタ バイオテクノロジー リミテッド アルブミン融合繊毛様神経栄養因子
JP2005535394A (ja) * 2002-08-13 2005-11-24 アルビオス テクノロジーズ インコーポレーティッド 選択的血漿交換方法
HUE042899T2 (hu) 2002-08-28 2019-07-29 Dyax Corp Eljárás szervek és szövetek tartósítására
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
EP1545611B1 (en) * 2002-09-06 2016-11-09 Alexion Pharmaceuticals, Inc. Method of treatment of asthma using antibodies to complement component c5
WO2004027064A2 (en) * 2002-09-18 2004-04-01 Centre Hospitalier De L'universite De Montreal (Chum) Ghrh analogues
US7432351B1 (en) 2002-10-04 2008-10-07 Mayo Foundation For Medical Education And Research B7-H1 variants
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
AU2003292273A1 (en) * 2002-12-20 2004-07-14 Karolinska Institutet Innovations Ab Asthma susceptibility locus
WO2004058817A1 (ja) * 2002-12-26 2004-07-15 Takeda Pharmaceutical Company Limited 新規タンパク質およびその用途
CA2513213C (en) * 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
ES2380147T3 (es) * 2003-02-11 2012-05-09 Shire Human Genetic Therapies, Inc. Diagnóstico y tratamiento de deficiencia múltiple de sulfatasas y otras usando una enzima generadora de formilglicina(FGE)
AU2004220459B2 (en) * 2003-03-12 2010-08-05 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
US7381410B2 (en) * 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
US20070041987A1 (en) * 2003-03-19 2007-02-22 Daniel Carter Fragments or polymers of albumin with tunable vascular residence time for use in therapeutic delivery and vaccine development
BRPI0409554A (pt) * 2003-04-04 2006-04-25 Univ Lausanne peptacorpo de fusão isolado e recombinante, seqüência de dna, vetor, célula hospedeira, composição farmacêutica e seu uso, kits, método para a produção do peptacorpo de fusão e seqüência de intensificador
KR20120035234A (ko) 2003-04-11 2012-04-13 메디뮨 엘엘씨 재조합 il?9 항체 및 그의 용도
WO2004094589A2 (en) * 2003-04-18 2004-11-04 Incyte Corporation Secreted proteins
WO2004101620A2 (en) * 2003-05-01 2004-11-25 Compound Therapeutics, Inc. Serum albumin scaffold-based proteins and uses thereof
US6987270B2 (en) 2003-05-07 2006-01-17 General Electric Company Method to account for event losses due to positron range in positron emission tomography and assay of positron-emitting isotopes
US7517655B2 (en) * 2003-06-30 2009-04-14 Nihon University Protein capable of deposition onto extracellular matrix
EP1644408A1 (en) 2003-07-15 2006-04-12 Barros Research Institute Eimeria tenella antigen for immunotherapy of coccidiosis
US8007805B2 (en) * 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
GB0320877D0 (en) * 2003-09-05 2003-10-08 Celltech R&D Ltd A protein involved in carcinoma
EP2248830A1 (en) 2003-11-04 2010-11-10 Novartis Vaccines and Diagnostics, Inc. Use of antagonist anti-CD40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection
WO2005054286A2 (en) * 2003-12-03 2005-06-16 Delta Biotechnology Limited Interleukin-11 fusion proteins
CN100379762C (zh) * 2003-12-08 2008-04-09 中国人民解放军军事医学科学院生物工程研究所 人血清白蛋白与白细胞介素2的融合蛋白及其编码基因
US9050378B2 (en) 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
WO2005058961A2 (en) 2003-12-12 2005-06-30 Amgen Inc. Antibodies specific for human galanin, and uses thereof
GB0329722D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Modified plasmid and use thereof
GB0329681D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Gene expression technique
JPWO2005061704A1 (ja) * 2003-12-24 2007-07-12 武田薬品工業株式会社 癌の予防・治療剤
BRPI0507026A (pt) * 2004-02-09 2007-04-17 Human Genome Sciences Inc proteìnas de fusão de albumina
SE0400489D0 (sv) * 2004-02-27 2004-02-27 Biovitrum Ab Therapeutic proteins
ATE458834T1 (de) * 2004-03-03 2010-03-15 Evotec Neurosciences Gmbh Diagnostische und therapeutische verwendung des mal2-gens und proteins bei neurodegenerativen krankheiten
JP2007528393A (ja) * 2004-03-11 2007-10-11 カイセラ バイオファーマシューティカルズ, インコーポレイテッド 皮膚の状態および毛の状態を予防および処置するための組成物および方法
US20050201959A1 (en) * 2004-03-11 2005-09-15 Vvii Newco 2003, Inc. Methods and compositions for altering skin coloration
CN102718867A (zh) 2004-03-12 2012-10-10 瓦斯基因治疗公司 结合ephb4、抑制血管发生和肿瘤生长的抗体
JP2007532666A (ja) 2004-04-14 2007-11-15 アヴィリッド インコーポレーテッド ウイルス核酸を対象とした修飾ヌクレアーゼを用いた組成物及びウイルス性疾患の予防並びに治療方法
EP2100904B1 (en) * 2004-04-23 2010-07-07 ConjuChem Biotechnologies Inc. Solid phase for use in a method for the purification of albumin conjugates
KR100599454B1 (ko) * 2004-04-27 2006-07-12 재단법인서울대학교산학협력재단 종양 억제자로 작용하는 aim3의 신규 용도
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
JP4948399B2 (ja) * 2004-06-03 2012-06-06 ヴァーミリオン インコーポレイテッド 末梢動脈疾患についてのバイオマーカー
WO2006009825A1 (en) * 2004-06-17 2006-01-26 Virun, Inc. Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents
EP1773375A1 (en) 2004-07-14 2007-04-18 University of Utah Research Foundation Netrin-related compositions and uses
CN101018874A (zh) * 2004-08-13 2007-08-15 千年药品公司 用于鉴定、评估、预防和治疗前列腺癌的基因、组合物、试剂盒和方法
CA2580921C (en) 2004-09-21 2016-04-12 Medimmune, Inc. Antibodies against and methods for producing vaccines for respiratory syncytial virus
US20060204512A1 (en) * 2004-09-23 2006-09-14 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2006039504A2 (en) * 2004-10-01 2006-04-13 Cell Ionix, Inc. Method and formulation for stem cells’ stimulation
CA2943949C (en) * 2004-10-06 2020-03-31 Mayo Foundation For Medical Education And Research B7-h1 and methods of diagnosis, prognosis, and treatment of cancer
WO2006042197A2 (en) * 2004-10-11 2006-04-20 The Board Of Trustees Of The Leland Standford Junior University Use of del-1 in hair, bone and cartilage regeneration
EP1809660B1 (en) 2004-10-25 2014-07-23 Immune System Key Ltd. A thymus-specific protein
KR100583350B1 (ko) * 2004-11-03 2006-06-05 (주)넥스젠 Fas-1 도메인을 함유하는 융합 단백질을 이용한상피세포재생인자의 생산 방법
ES2312037T3 (es) * 2004-11-09 2009-02-16 Ares Trading S.A. Metodo para puruficar fsh.
EP2330200B1 (en) 2004-12-23 2017-04-05 Albumedix A/S Gene expression technique
US20090196850A1 (en) 2005-01-06 2009-08-06 Novo Nordisk A/S Anti-Kir Combination Treatments and Methods
US20060178301A1 (en) * 2005-02-04 2006-08-10 Mathias Jurs Albumin-fused ciliary neurotrophic factor
EP1853718B1 (en) 2005-02-15 2015-08-05 Duke University Anti-cd19 antibodies and uses in oncology
US20110230407A1 (en) * 2005-03-14 2011-09-22 Alexander Yuzhakov Hepatocyte growth factor pathway activators in demyelinating diseases and central nervous system trauma
CN101147068A (zh) * 2005-03-23 2008-03-19 惠氏公司 Gdf-8调节剂的检测
MX2007011405A (es) * 2005-03-23 2007-10-11 Wyeth Corp Deteccion de una respuesta inmune para agentes moduladores de crecimiento y la diferenciacion del factor 8 (gdf 8).
BRPI0609079A2 (pt) 2005-04-18 2010-11-16 Novo Nordisk As peptìdeo, composição farmacêutica, método para o tratamento de cáncer, uso de um peptìdeo construto de ácido nucleico, vetor, hospedeiro, e, anticorpo
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
WO2006114115A1 (de) 2005-04-26 2006-11-02 Trion Pharma Gmbh Kombination von antikörpern mit glukokortikoiden zur behandlung von krebs
US9585932B2 (en) 2005-04-29 2017-03-07 Peter C. Dowling Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders
WO2007052154A2 (en) 2005-04-29 2007-05-10 University Of Medicine And Dentistry Of New Jersey Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
US9345745B2 (en) * 2005-04-29 2016-05-24 Bo Wang Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
EP2221316A1 (en) 2005-05-05 2010-08-25 Duke University Anti-CD19 antibody therapy for autoimmune disease
EP1951749A2 (en) * 2005-05-12 2008-08-06 Zymogenetics, Inc. Methods of using phhla2 to co-stimulate t-cells
DK1907000T4 (da) 2005-06-08 2020-03-30 The President And Fellows Of Harvard College Fremgangsmåder og sammensætninger til behandling af persisterende HIV-infektioner ved hæmning af reaktionsvejen for programmeret celledød 1 (PD-1).
WO2007014167A2 (en) * 2005-07-22 2007-02-01 Five Prime Therapeutics, Inc. Compositions for and methods of treating epithelial diseases with growth factors
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
ES2579602T3 (es) 2005-08-10 2016-08-12 Macrogenics, Inc. Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de uso de estos
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
EP1917276B1 (en) * 2005-08-26 2018-03-21 Ares Trading S.A. Process for the preparation of glycosylated interferon beta
US7713715B2 (en) * 2005-09-06 2010-05-11 University Of Tennessee Research Foundation Method for diagnosing infections
US20090099031A1 (en) * 2005-09-27 2009-04-16 Stemmer Willem P Genetic package and uses thereof
US20070191272A1 (en) * 2005-09-27 2007-08-16 Stemmer Willem P Proteinaceous pharmaceuticals and uses thereof
US7846445B2 (en) * 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US7855279B2 (en) * 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US20080274096A1 (en) * 2005-10-03 2008-11-06 Astrazeneca Ab Fusion Proteins Having a Modulated Half-Life in Plasma
US8168592B2 (en) * 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
WO2007075326A2 (en) * 2005-12-09 2007-07-05 Seattle Genetics, Inc. Methods of using cd40 binding agents
EP1960419B1 (en) * 2005-12-09 2016-03-16 Ares Trading S.A. Method for purifying fsh or a fsh mutant
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
AU2006329215A1 (en) * 2005-12-22 2007-06-28 Conjuchem Biotechnologies Inc. Process for the production of preformed conjugates of albumin and a therapeutic agent
US20100015642A1 (en) * 2006-01-05 2010-01-21 Kwon Eugene D B7-h1 and survivin in cancer
US20090215084A1 (en) * 2006-01-05 2009-08-27 Mayo Foundation For Medical Education And Research B7-h1 and b7-h4 in cancer
AU2007207544A1 (en) 2006-01-17 2007-07-26 Health Research, Inc. Heteroduplex tracking assay
EP1816201A1 (en) * 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
WO2007097961A1 (en) * 2006-02-16 2007-08-30 Massachusetts Eye & Ear Infirmary Use of azurocidin inhibitors in prevention and treatment of ocular vascular leakage
EP2540741A1 (en) 2006-03-06 2013-01-02 Aeres Biomedical Limited Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
US7863426B2 (en) * 2006-04-05 2011-01-04 Abbott Biotechnology Ltd. Antibody purification
US20100222554A1 (en) * 2006-04-11 2010-09-02 Thomas Weimer Method of Increasing the In Vivo Recovery of Therapeutic Polypeptides
WO2007124361A2 (en) * 2006-04-20 2007-11-01 Mayo Foundation For Medical Education And Research Soluble b7-h1
US8334365B2 (en) 2006-06-07 2012-12-18 Human Genome Sciences, Inc. Albumin fusion proteins
US7939632B2 (en) 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
EP1867660A1 (en) 2006-06-14 2007-12-19 CSL Behring GmbH Proteolytically cleavable fusion protein comprising a blood coagulation factor
ES2889920T3 (es) * 2006-06-14 2022-01-14 Csl Behring Gmbh Proteínas de fusión escindibles proteolíticamente con alta actividad específica molar
AU2013202566C1 (en) * 2006-06-14 2018-07-12 Csl Behring Gmbh Proteolytically cleavable fusion protein comprising a blood coagulation factor
US9139611B2 (en) * 2006-07-13 2015-09-22 Novozymes Biopharma Dk A/S Process for preparing particles of proteinaceous material
AU2007278994B2 (en) 2006-07-24 2013-08-15 Biorexis Pharmaceutical Corporation Exendin fusion proteins
US20090208480A1 (en) * 2006-08-04 2009-08-20 Yue Huang Long half-life recombinant butyrylcholinesterase
CN103230598A (zh) * 2006-09-06 2013-08-07 费斯生物制药公司 融合肽治疗组合物
EP2069396B1 (en) 2006-09-08 2015-10-21 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
CA2667678A1 (en) * 2006-10-25 2008-07-24 Amgen Inc. Toxin peptide therapeutic agents
US8475784B2 (en) 2006-10-26 2013-07-02 Novo Nordisk A/S IL-21 variants
AU2007322265B2 (en) 2006-11-07 2013-06-20 Merck Sharp & Dohme Corp. Antagonists of PCSK9
MX2009006398A (es) 2006-12-12 2009-06-23 Biorexis Pharmaceutical Corp Genotecas de proteinas de fusion de transferrina.
WO2008074840A2 (en) 2006-12-19 2008-06-26 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
EP2557090A3 (en) 2006-12-19 2013-05-29 Ablynx N.V. Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
EP1935430A1 (en) * 2006-12-22 2008-06-25 CSL Behring GmbH Modified coagulation factors with prolonged in vivo half-life
WO2008077616A1 (en) 2006-12-22 2008-07-03 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
CN107011431B (zh) 2007-01-30 2020-11-06 埃皮瓦克斯公司 调节性t细胞表位、组合物及其用途
EP2109457B1 (en) 2007-02-12 2016-01-06 CSL Behring GmbH Therapeutic application of kazal-type serine protease inhibitors
US8263353B2 (en) 2007-03-27 2012-09-11 Merck Sharp & Dohme Corp. Method for detecting autoprocessed, secreted PCSK9
WO2008137915A2 (en) 2007-05-07 2008-11-13 Medimmune, Llc Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
LT3072525T (lt) 2007-05-14 2018-05-10 Astrazeneca Ab Bazofilų lygių mažinimo būdai
CA2687141C (en) 2007-05-22 2014-04-01 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
JP2010533649A (ja) 2007-07-13 2010-10-28 ザ ジョンズ ホプキンス ユニバーシティー B7−dc改変体
WO2009012502A1 (en) * 2007-07-19 2009-01-22 The Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Self- anchoring mems intrafascicular neural electrode
EP2185701A4 (en) * 2007-08-15 2011-03-02 Amunix Operating Inc COMPOSITIONS AND METHODS FOR ENHANCING THE PRODUCTION OF RECOMBINANT POLYPEPTIDES
RU2571515C2 (ru) 2007-08-29 2015-12-20 Санофи-Авентис Гуманизированные антитела к cxcr5, их производные и их применение
JP2009055838A (ja) * 2007-08-31 2009-03-19 Nipro Corp 融合タンパク質、該融合タンパク質に関連する遺伝子、ベクター、形質転換体及び抗炎症性医薬組成物
WO2009039409A1 (en) * 2007-09-21 2009-03-26 The Regents Of The University Of Californina Targeted interferon demonstrates potent apoptotic and anti-tumor activities
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
AU2008314687A1 (en) * 2007-10-22 2009-04-30 Merck Serono S.A. Method for purifying Fc-fusion proteins
US20100256337A1 (en) * 2007-10-22 2010-10-07 Merck Serono Sa Method for purifying an fc-containing protein
US9308257B2 (en) 2007-11-28 2016-04-12 Medimmune, Llc Protein formulation
ES2518415T3 (es) 2007-12-21 2014-11-05 Medimmune Limited Elementos de unión para receptor alfa de interleucina-4 (IL-4Ralfa)
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
WO2009097318A1 (en) * 2008-01-28 2009-08-06 Bristol-Myers Squibb Company A fluorescence polarization binding assay for characterizing glucokinase ligands
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
US20110020325A1 (en) * 2008-02-29 2011-01-27 Kwon Eugene D Methods for reducing granulomatous inflammation
JP5020135B2 (ja) * 2008-03-19 2012-09-05 ソニーモバイルコミュニケーションズ, エービー 携帯端末装置およびコンピュータプログラム
ES2563553T3 (es) 2008-04-01 2016-03-15 Novo Nordisk A/S Conjugados de insulina-albúmina
AU2009235467A1 (en) 2008-04-07 2009-10-15 Ablynx Nv Single variable domains against the Notch pathways
EP2274331B1 (en) 2008-05-02 2013-11-06 Novartis AG Improved fibronectin-based binding molecules and uses thereof
AU2013202564B2 (en) * 2008-06-24 2015-09-17 Csl Behring Gmbh Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life
EP2865760B1 (en) 2008-06-24 2017-10-11 CSL Behring GmbH Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
EP4074327A1 (en) 2008-06-27 2022-10-19 Duke University Therapeutic agents comprising elastin-like peptides
CA2767331A1 (en) * 2008-07-10 2010-01-14 Angion Biomedica Corp. Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity
WO2010010119A1 (en) 2008-07-22 2010-01-28 Ablynx Nv Amino acid sequences directed against multitarget scavenger receptors and polypeptides
PT2328616E (pt) 2008-08-05 2015-08-26 Novartis Ag Composições e métodos para anticorpos dirigidos à proteína c5 do complemento
EA023148B1 (ru) 2008-08-25 2016-04-29 Эмплиммьюн, Инк. Композиции на основе антагонистов pd-1 и их применение
EA201170375A1 (ru) * 2008-08-25 2012-03-30 Эмплиммьюн, Инк. Антагонисты pd-1 и способы их применения
NZ591488A (en) 2008-09-07 2012-11-30 Glyconex Inc Anti-extended type i glycosphingolipid antibody, derivatives thereof and use
JP5933975B2 (ja) 2008-11-12 2016-06-15 メディミューン,エルエルシー 抗体製剤
BRPI0921586A2 (pt) * 2008-11-18 2019-09-24 Merrimack Pharmaceuticals Inc articuladores de albumina de soro humana e conjugados destes
SI2370593T1 (sl) 2008-11-28 2016-08-31 Emory University Postopek za določanje učinkovitosti antagonista pd-1
KR20200047793A (ko) 2008-12-09 2020-05-07 제넨테크, 인크. 항-pd-l1 항체 및 t 세포 기능을 향상시키기 위한 그의 용도
US8748115B2 (en) 2008-12-12 2014-06-10 Merck Sharp & Dohme Corp. PCSK9 immunoassay
AU2010203712A1 (en) 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
SG196821A1 (en) 2009-01-16 2014-02-13 Teva Pharma New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
US8852608B2 (en) 2009-02-02 2014-10-07 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
US8703717B2 (en) * 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
SI2393828T1 (sl) 2009-02-03 2017-01-31 Amunix Operating Inc. Podaljšani rekombinantni polipetidi in sestavki, ki jih obsegajo
US8680050B2 (en) * 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
SG2014012918A (en) 2009-02-11 2014-04-28 Novozymes Biopharma Dk As Albumin variants and conjugates
CA2755336C (en) 2009-03-20 2015-07-14 Amgen Inc. Carrier immunoglobulins and uses thereof
EP2427486B1 (en) 2009-05-07 2015-02-25 Novozymes Biopharma DK A/S Method for purifying albumin
EP2258398A1 (en) * 2009-05-26 2010-12-08 Araclón Biotech, S. L. Albumin-amyloid peptide conjugates and uses thereof
US11512326B2 (en) * 2009-05-26 2022-11-29 University Of Florida Research Foundation, Incorporated Small angiotensin peptide expression system in mammalian cells
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
WO2010144508A1 (en) 2009-06-08 2010-12-16 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
CA2769822C (en) 2009-08-13 2019-02-19 The Johns Hopkins University Methods of modulating immune function
EP2467166A2 (en) 2009-08-20 2012-06-27 CSL Behring GmbH Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
US10420862B2 (en) 2009-08-24 2019-09-24 Aresenal AAA, LLC. In-situ forming foams for treatment of aneurysms
US9173817B2 (en) 2009-08-24 2015-11-03 Arsenal Medical, Inc. In situ forming hemostatic foam implants
US9044580B2 (en) 2009-08-24 2015-06-02 Arsenal Medical, Inc. In-situ forming foams with outer layer
US20110202016A1 (en) * 2009-08-24 2011-08-18 Arsenal Medical, Inc. Systems and methods relating to polymer foams
EP3222287A1 (en) 2009-08-24 2017-09-27 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
US8451450B2 (en) * 2009-09-14 2013-05-28 Bio-Rad Laboratories, Inc. Near real time optical phase conjugation
UY32920A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moleculas de unión biespecíficas para la terapia anti-angiogénesis
UY32917A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moléculas de unión a dll-4
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
HUE036549T2 (hu) 2009-10-07 2018-07-30 Macrogenics Inc A fukozilezés mértékének megváltozása miatt javított effektor funkciót mutató, Fc-régiót tartalmazó polipeptidek, valamint eljárások alkalmazásukra
WO2011051278A1 (en) * 2009-10-26 2011-05-05 Externautics S.P.A. Lung tumor markers and methods of use thereof
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
JP2013509194A (ja) 2009-10-30 2013-03-14 メルク・シャープ・エンド・ドーム・コーポレイション Ax213およびax132pcsk9アンタゴニストおよびバリアント
EP3421491A3 (en) 2009-10-30 2019-03-27 Albumedix Ltd Albumin variants
CN102596249A (zh) 2009-10-30 2012-07-18 默沙东公司 Ax1和ax189 pcsk9拮抗剂和变体
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
CA2817671A1 (en) * 2009-11-17 2011-05-26 Universite De Montreal Heteropeptides useful for reducing nonspecific adsorption
ME02964B (me) * 2009-12-06 2018-07-20 Himerni i hibridni polipeptidi faktora viii-fc, i postupci za njihovu upotrebu
WO2011071926A1 (en) 2009-12-08 2011-06-16 Teva Pharmaceutical Industries Ltd. Bche albumin fusions for the treatment of cocaine abuse
WO2011073180A1 (en) 2009-12-14 2011-06-23 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
US8729245B2 (en) 2009-12-21 2014-05-20 Pharmathene, Inc. Recombinant butyrylcholinesterases and truncates thereof
HRP20220107T1 (hr) 2010-01-06 2022-04-15 Takeda Pharmaceutical Company Limited Proteini koji vežu kalikrein plazme
TWI513466B (zh) 2010-01-20 2015-12-21 Boehringer Ingelheim Int 抗凝血劑解毒劑
BR112012018162A2 (pt) 2010-01-22 2017-10-03 Novo Nordisk Healthcare Ag Compostos de hormônio do crescimento estáveis
RS59459B1 (sr) 2010-01-22 2019-11-29 Novo Nordisk Healthcare Ag Hormoni rasta sa produženom in-vivo efikasnošću
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
WO2011100460A2 (en) * 2010-02-11 2011-08-18 Ecole Polytechnique Federale De Lausanne Ccr7 ligand delivery and co-delivery in immunotherapy
BR112012022102A2 (pt) 2010-03-03 2017-01-10 Boehringer Ingelheim Int polipeptídeos de ligação a a-beta.
EP2371857A1 (en) 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
KR20130070576A (ko) 2010-04-09 2013-06-27 노보자임스 바이오파마 디케이 에이/에스 알부민 유도체 및 변이체
SG185415A1 (en) 2010-05-06 2012-12-28 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
ES2949159T3 (es) 2010-05-06 2023-09-26 Novartis Ag Composiciones y métodos de uso para anticuerpos terapéuticos de proteína 6 relacionada con lipoproteínas de baja densidad (LRP6)
KR20130080790A (ko) 2010-05-20 2013-07-15 아블린쓰 엔.브이. Her3와 관련된 생물학적 물질들
MY192639A (en) 2010-07-09 2022-08-29 Bioverativ Therapeutics Inc Factor ix polypeptides and methods of use thereof
US9611310B2 (en) 2010-07-09 2017-04-04 Bioverativ Therapeutics Inc. Systems for factor VIII processing and methods thereof
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9518087B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
EA036314B1 (ru) 2010-08-20 2020-10-26 Новартис Аг Выделенные антитела к рецептору эпидермального фактора роста-3 (her3) и их фрагменты, фармацевтическая композиция, содержащая эти антитела и фрагменты, и их применение для лечения рака
CN103260646B (zh) 2010-08-27 2016-01-13 施特姆森特克斯股份有限公司 Notum蛋白调节剂和使用方法
WO2012031273A2 (en) 2010-09-03 2012-03-08 Stem Centrx, Inc. Novel modulators and methods of use
US20120225081A1 (en) 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
AU2011305306C1 (en) 2010-09-22 2016-02-18 Amgen Inc. Carrier immunoglobulins and uses thereof
BR112013007388B1 (pt) * 2010-09-28 2022-01-04 Amylin Pharmaceuticals, Llc Polipeptídeo tendo domínio de ligação de albumina e leptina, seu uso no tratamento de doenças, bem como composição farmacêutica que o compreende
DK3590949T3 (da) 2010-10-01 2022-07-11 Modernatx Inc Ribonukleinsyrer indeholdende n1-methyl-pseudouracil og anvendelse heraf
US8892184B2 (en) 2010-10-18 2014-11-18 Siemens Medical Solutions Usa, Inc. Systems and methods for reducing interference in a dual modality imaging system
US8853490B2 (en) * 2010-10-26 2014-10-07 Pioneer Hi Bred International Inc Antifungal proteins and methods of use
EP2635598A1 (en) 2010-11-01 2013-09-11 Novozymes Biopharma DK A/S Albumin variants
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
EP3578568A3 (en) 2010-11-08 2020-01-08 Ablynx N.V. Cxcr2 binding polypeptides
US9066974B1 (en) 2010-11-13 2015-06-30 Sirbal Ltd. Molecular and herbal combinations for treating psoriasis
US9095606B1 (en) 2010-11-13 2015-08-04 Sirbal Ltd. Molecular and herbal combinations for treating psoriasis
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
PE20171143A1 (es) 2010-12-08 2017-08-10 Stem Centrx Inc Nuevos moduladores y metodos para su uso
JP5894085B2 (ja) 2010-12-28 2016-03-23 大日本住友製薬株式会社 アルツハイマー病の診断薬及び診断方法
US20120171195A1 (en) 2011-01-03 2012-07-05 Ravindranath Mepur H Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use
IL269565B2 (en) 2011-01-06 2024-06-01 Dyax Corp KALLIKREIN PLASMA BINDING PROTEINS
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
US20140105898A1 (en) 2011-02-28 2014-04-17 Istituto Di Ricovero E Cura A Carattere Scientific Materno-Infantile Burlo Garo Apoptosis-inducing molecules and uses therefor
ES2676878T3 (es) 2011-03-03 2018-07-25 Zymeworks Inc. Diseño de armazón de heteromultímero multivalente y constructos
CN103415301A (zh) 2011-03-09 2013-11-27 德国杰特贝林生物制品有限公司 用于与包括与人造表面接触的医疗操作一起施用的fxii抑制剂
EP2497489A1 (en) 2011-03-09 2012-09-12 CSL Behring GmbH Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
BR112013023674A2 (pt) 2011-03-16 2016-12-13 Amgen Inc inibidores potentes e seletivos de nav1.3 e nav1.7
US20130344074A1 (en) 2011-03-16 2013-12-26 Sanofi Uses of a dual v region antibody-like protein
WO2012135500A1 (en) 2011-03-29 2012-10-04 The General Hospital Corporation Engineered thioredoxin-like fold proteins
CN103476459A (zh) 2011-03-30 2013-12-25 勃林格殷格翰国际有限公司 抗凝血剂解毒剂
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US20130078247A1 (en) 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
CA2830923A1 (en) 2011-04-15 2012-10-18 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
EP2515112B1 (en) * 2011-04-22 2015-08-12 Sysmex Corporation Method for electrochemically detecting analyte
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
KR20140027307A (ko) 2011-05-05 2014-03-06 노보자임스 바이오파마 디케이 에이/에스 알부민 변이체
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
US9561274B2 (en) 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
PT2717898T (pt) 2011-06-10 2019-05-20 Bioverativ Therapeutics Inc Compostos pró-coagulantes e processos para a sua utilização
WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
CN103917563A (zh) 2011-06-28 2014-07-09 英伊布里克斯有限责任公司 丝氨酸蛋白酶抑制蛋白融合多肽及其使用方法
AU2012280474A1 (en) 2011-07-01 2014-01-16 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
JP6247210B2 (ja) 2011-07-05 2017-12-13 アルブミディクス アクティーゼルスカブ アルブミン製剤及び用途
DK2729160T3 (da) 2011-07-08 2019-07-01 Aegerion Pharmaceuticals Inc Manipulerede polypeptider, der har forbedret virkningstid og reduceret immunogenicitet
BR112014000474A2 (pt) 2011-07-08 2017-02-21 Bayer Ip Gmbh proteínas de fusão libertadoras de relaxina e suas utilizações
JP2014520869A (ja) * 2011-07-18 2014-08-25 アルツ バイオロジクス アクティーゼルスカブ 長期作用性で生物学的活性が有る黄体形成ホルモン(lh)化合物
BR112014001104B1 (pt) 2011-07-22 2022-12-06 Csl Behring Gmbh Anticorpo monoclonal antifator xii/xiia-beta ou fragmento de ligação ao antígeno do mesmo, seu método de produção, ácido nucleico, vetor, dispositivo médico e composição farmacêutica
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
LT3682905T (lt) 2011-10-03 2022-02-25 Modernatx, Inc. Modifikuoti nukleozidai, nukleotidai ir nukleorūgštys bei jų naudojimas
WO2013067057A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
HK1201855A1 (en) 2011-11-01 2015-09-11 Bionomics, Inc. Antibodies and methods of treating cancer
US8993831B2 (en) * 2011-11-01 2015-03-31 Arsenal Medical, Inc. Foam and delivery system for treatment of postpartum hemorrhage
WO2013067060A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
US10598653B2 (en) 2011-11-01 2020-03-24 Bionomics Inc. Methods of blocking cancer stem cell growth
JP2015502741A (ja) 2011-11-04 2015-01-29 ノバルティス アーゲー 低比重リポタンパク質関連タンパク質6(lrp6)−半減期延長構築物
PT2773671T (pt) 2011-11-04 2021-12-14 Zymeworks Inc Geração de anticorpo heterodimérico estável com mutações no domínio fc
WO2013075066A2 (en) 2011-11-18 2013-05-23 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
BR112014013568A2 (pt) 2011-12-05 2017-06-13 Novartis Ag anticorpos para o receptor do fator de crescimento epidermal 3 (her3) direcionados para o domínio ii do her3
EP3590538A1 (en) 2011-12-05 2020-01-08 Novartis AG Antibodies for epidermal growth factor receptor 3 (her3)
CA2859387A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
EA201491214A1 (ru) 2011-12-21 2015-02-27 Новартис Аг Композиции и способы применения антител, нацеленных на фактор p
JP6127063B2 (ja) 2011-12-22 2017-05-10 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 中枢神経系の続発性浮腫の治療のためのc1インヒビターの使用
US10800847B2 (en) 2012-01-11 2020-10-13 Dr. Mepur Ravindranath Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use
US20130177574A1 (en) 2012-01-11 2013-07-11 Paul I. Terasaki Foundation Laboratory ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
CN111499761A (zh) 2012-01-12 2020-08-07 比奥贝拉蒂治疗公司 嵌合因子viii多肽及其用途
EP2623110A1 (en) 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
NZ628014A (en) 2012-02-15 2016-09-30 Biogen Ma Inc Recombinant factor viii proteins
ES2781773T3 (es) 2012-02-15 2020-09-07 Ecole Polytechnique Fed Lausanne Epfl Productos terapéuticos de unión a los eritrocitos
EP2814502B1 (en) * 2012-02-15 2017-09-13 CSL Behring GmbH Von willebrand factor variants having improved factor viii binding affinity
AU2012327217B2 (en) 2012-02-15 2016-05-12 Bioverativ Therapeutics Inc. Factor VIII compositions and methods of making and using same
AU2013203459B2 (en) 2012-02-24 2016-11-03 Abbvie Stemcentrx Llc DLL3 modulators and methods of use
AU2013226340B2 (en) 2012-02-27 2017-06-22 Ablynx N.V. CX3CR1-binding polypeptides
CN104736559B (zh) 2012-03-16 2022-04-08 阿尔布梅迪克斯医疗有限公司 白蛋白变体
GB201204868D0 (en) * 2012-03-20 2012-05-02 San Raffaele Centro Fond Peptides
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US9550819B2 (en) 2012-03-27 2017-01-24 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9120853B2 (en) 2012-04-27 2015-09-01 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
WO2013166290A1 (en) 2012-05-04 2013-11-07 Abbvie Biotherapeutics Inc. P21 biomarker assay
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
WO2013166594A1 (en) 2012-05-10 2013-11-14 Zymeworks Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
WO2013177386A1 (en) 2012-05-24 2013-11-28 Abbvie Biotherapeutics Inc. Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
CN104507319B (zh) 2012-05-30 2018-08-03 拜尔农作物科学股份公司 包含生物防治剂和选自脂质膜合成抑制剂、黑素生物合成抑制剂、核酸合成抑制剂或信号转导抑制剂的杀真菌剂的组合物
MX353877B (es) 2012-05-30 2018-02-01 Bayer Cropscience Ag Composiciones que comprenden un agente de control biologico y un insecticida.
BR112014029123A2 (pt) 2012-05-30 2017-06-27 Bayer Cropscience Ag composições compreendendo um agente de controle biológico e um inseticida
AU2013269661B2 (en) 2012-05-30 2016-10-27 Bayer Cropscience Ag Compositions comprising a biological control agent and an insecticide
CN104507317B (zh) 2012-05-30 2019-11-15 拜尔农作物科学股份公司 包含生物防治剂和杀真菌剂的组合物、及其用途、试剂盒
AR091196A1 (es) 2012-05-30 2015-01-21 Bayer Cropscience Ag Composicion que comprende un agente de control biologico y un fungicida
PL2854550T3 (pl) 2012-05-30 2019-01-31 Bayer Cropscience Ag Kompozycja zawierająca środek do kontroli biologicznej i środek grzybobójczy
AU2013269725B2 (en) 2012-05-30 2016-10-13 Bayer Cropscience Ag Compositions comprising a biological control agent and an insecticide
MX356531B (es) 2012-05-30 2018-06-01 Bayer Cropscience Ag Composicion que comprende un agente de control biologico y un fungicida seleccionado de inhibidores de la cadena respiratoria en el complejo iii.
BR112014029553B1 (pt) 2012-05-30 2019-11-26 Bayer Cropscience Ag composição que compreende um agente de controle biológico e um fungicida, seus usos, semente resistente a patógeno, método para reduzir os danos totais em plantas e em partes de plantas, e kit de partes
EP2854534B1 (en) 2012-05-30 2018-04-11 Bayer Cropscience AG Compositiions comprising a biological control agent and an insecticide
NZ742941A (en) 2012-05-30 2019-09-27 Bayer Cropscience Ag Composition comprising a biological control agent and a fungicide selected from inhibitors of the mitosis and cell division or compounds having a multi-site action
EP4079316A1 (en) 2012-06-08 2022-10-26 Bioverativ Therapeutics Inc. Procoagulant compounds
WO2013185114A2 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Chimeric clotting factors
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US10656156B2 (en) 2012-07-05 2020-05-19 Mepur Ravindranath Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
PH12015500039B1 (en) 2012-07-11 2024-06-28 Bioverativ Therapeutics Inc Factor viii complex with xten and von willebrand factor protein, and uses thereof
IN2015DN01115A (h) 2012-07-13 2015-06-26 Zymeworks Inc
US9345766B2 (en) 2012-08-30 2016-05-24 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-ERBB3 agents
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
AU2013309506A1 (en) 2012-09-02 2015-03-12 Abbvie Inc. Methods to control protein heterogeneity
HK1213767A1 (zh) 2012-10-18 2016-07-15 Bioverativ Therapeutics Inc. 使用固定劑量凝血因子的方法
GB2512156A (en) 2012-11-08 2014-09-24 Novozymes Biopharma Dk As Albumin variants
BR112015010740B1 (pt) 2012-11-13 2024-01-30 Biontech Ag Agentes para tratamento de doenças cancerosas expressando claudina
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
HRP20210517T1 (hr) 2012-12-05 2021-05-14 Novartis Ag Pripravci i postupci za protutijela usmjerena na epo
EP3907237A1 (en) 2012-12-20 2021-11-10 Amgen Inc. Apj receptor agonists and uses thereof
HK1217670A1 (zh) 2013-01-15 2017-01-20 Teva Pharmaceutical Industries Ltd. Albu-bche调配物、其制造方法和用途
KR101503907B1 (ko) * 2013-01-17 2015-03-20 서울대학교산학협력단 흉막폐렴균과 마이코플라즈마 하이오뉴모니아 감염 질환 예방을 위한 재조합 단백질 백신
WO2014120619A2 (en) 2013-01-30 2014-08-07 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
EP2953469A1 (en) 2013-02-11 2015-12-16 Bayer Cropscience LP Compositions comprising a streptomyces-based biological control agent and another biological control agent
EP4223772A3 (en) 2013-02-15 2023-10-18 Bioverativ Therapeutics Inc. Optimized factor viii gene
WO2014125082A1 (en) 2013-02-16 2014-08-21 Novozymes Biopharma Dk A/S Pharmacokinetic animal model
DK2961422T3 (en) 2013-02-28 2017-01-16 Csl Behring Gmbh Therapeutic agent for amniotic fluid embolism
USRE48805E1 (en) 2013-03-06 2021-11-02 Vision Global Holdings Ltd. Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein
US9255262B2 (en) * 2013-03-06 2016-02-09 Vision Global Holdings Ltd. Albumin-binding arginine deminase and the use thereof
EP2964255B1 (en) 2013-03-08 2020-11-04 CSL Behring GmbH Treatment and prevention of remote ischemia-reperfusion injury
WO2014164703A1 (en) 2013-03-11 2014-10-09 University Of Florida Research Foundation, Inc. Delivery of card protein as therapy for occular inflammation
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
UY35397A (es) 2013-03-12 2014-10-31 Amgen Inc INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7
EP2968587A2 (en) 2013-03-13 2016-01-20 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
WO2014159813A1 (en) 2013-03-13 2014-10-02 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
CN105246916A (zh) 2013-03-14 2016-01-13 诺华股份有限公司 针对notch 3的抗体
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
CA2899089C (en) 2013-03-15 2021-10-26 Biogen Ma Inc. Factor ix polypeptide formulations
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP2978451B1 (en) 2013-03-29 2019-11-27 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
WO2014166836A1 (en) * 2013-04-05 2014-10-16 Novo Nordisk A/S Growth hormone compound formulation
DK2796145T3 (da) 2013-04-22 2018-01-29 Csl Ltd Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
UY35620A (es) 2013-06-21 2015-01-30 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
AR096601A1 (es) 2013-06-21 2016-01-20 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
KR20160026905A (ko) 2013-06-28 2016-03-09 체에스엘 베링 게엠베하 인자 xii 억제제 및 c1-억제제를 이용한 병용 치료요법
CN113831415A (zh) 2013-06-28 2021-12-24 比奥贝拉蒂治疗公司 具有xten的凝血酶可裂解连接子和其用途
CN104342420B (zh) * 2013-07-30 2017-09-15 惠觅宙 一种重组长效人透明质酸酶、其编码基因、生产方法及应用
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子viii-xten融合物及其用途
EP4108254A1 (en) 2013-08-14 2022-12-28 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
WO2015026423A1 (en) 2013-08-20 2015-02-26 Infusion Medical, Inc. Syringe fill system and method
KR20160044042A (ko) 2013-08-28 2016-04-22 스템센트알엑스 인코포레이티드 부위-특이적 항체 접합 방법 및 조성물
JP2016538318A (ja) 2013-08-28 2016-12-08 ステムセントリックス, インコーポレイテッド 新規sez6モジュレーターおよび使用方法
EP3048899B1 (en) 2013-09-25 2021-09-08 Bioverativ Therapeutics Inc. On-column viral inactivation methods
CN103468662A (zh) * 2013-09-29 2013-12-25 惠觅宙 一种重组人透明质酸酶、其生产纯化方法、制剂及使用方法与应用
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
ES2714708T3 (es) 2013-10-01 2019-05-29 Mayo Found Medical Education & Res Procedimientos para el tratamiento de cáncer en pacientes con niveles elevados de Bim
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
WO2015057403A2 (en) * 2013-10-17 2015-04-23 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of inflammatory bowel disease
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015066279A2 (en) 2013-10-30 2015-05-07 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
PL3063275T3 (pl) 2013-10-31 2020-03-31 Resolve Therapeutics, Llc Terapeutyczne fuzje nukleaza-albumina i sposoby
US10208102B2 (en) * 2013-11-01 2019-02-19 University Of Oslo Albumin variants and uses thereof
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2015089283A1 (en) 2013-12-11 2015-06-18 Cytomx Therapeutics, Inc. Antibodies that bind activatable antibodies and methods of use thereof
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
CA2935903A1 (en) 2014-01-09 2015-07-16 Hadasit Medical Research Services And Development Ltd. Improved cell compositions and methods for cancer therapy
HUE066567T2 (hu) 2014-01-10 2024-08-28 Bioverativ Therapeutics Inc VIII-as faktor kimérafehérjék és alkalmazásuk
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
AU2015233084B2 (en) 2014-02-21 2020-12-17 Anokion Sa Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
ES2911714T3 (es) 2014-03-11 2022-05-20 Univ Florida Proteína M013 expresada por AAV como un terapéutico antiinflamatorio para su uso en un método de tratamiento de enfermedad ocular inflamatoria
US20170107294A1 (en) * 2014-03-21 2017-04-20 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
WO2015160618A1 (en) 2014-04-16 2015-10-22 Bayer Cropscience Lp Compositions comprising ningnanmycin and a biological control agent
WO2015164615A1 (en) 2014-04-24 2015-10-29 University Of Oslo Anti-gluten antibodies and uses thereof
CN106488987A (zh) 2014-05-02 2017-03-08 塞勒尼斯医疗控股公司 Hdl疗法标志物
US10302653B2 (en) 2014-05-22 2019-05-28 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti B7-H1 antibodies
CN105198999A (zh) * 2014-05-27 2015-12-30 上海生物制品研究所有限责任公司 一种融合蛋白、其制备方法及其应用
USD750768S1 (en) 2014-06-06 2016-03-01 Anutra Medical, Inc. Fluid administration syringe
USD763433S1 (en) 2014-06-06 2016-08-09 Anutra Medical, Inc. Delivery system cassette
USD774182S1 (en) 2014-06-06 2016-12-13 Anutra Medical, Inc. Anesthetic delivery device
EP4257152A3 (en) 2014-06-10 2023-12-06 Amgen Inc. Apelin polypeptides
AU2015276089B2 (en) 2014-06-18 2021-03-18 Csl Behring Gmbh Therapy using a Factor XII inhibitor in a neurotraumatic disorder
EP3157947A1 (en) 2014-06-23 2017-04-26 Novartis AG Hsa-gdf-15 fusion polypeptide and use thereof
MX2016016063A (es) 2014-06-24 2017-03-10 Novo Nordisk As Proteinas de fusion de citocina-1 inhibidora de macrofagos (mic-1) y usos de las mismas.
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
EP3171896A4 (en) 2014-07-23 2018-03-21 Mayo Foundation for Medical Education and Research Targeting dna-pkcs and b7-h1 to treat cancer
TWI710570B (zh) 2014-07-30 2020-11-21 美商Ngm生物製藥公司 用於治療代謝異常之組成物及方法
WO2016020880A2 (en) 2014-08-07 2016-02-11 Novartis Ag Angiopoietin-like 4 antibodies and methods of use
US9988443B2 (en) 2014-08-07 2018-06-05 Novartis Ag Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
TWI563001B (en) 2014-08-22 2016-12-21 Univ Nat Cheng Kung Disintegrin variants and pharmaceutical uses thereof
WO2016044529A1 (en) 2014-09-17 2016-03-24 Bayer Cropscience Lp Compositions comprising recombinant bacillus cells and another biological control agent
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
CR20170110A (es) 2014-09-26 2017-05-08 Bayer Pharma AG Derivados estabilizados de adrenomedulina y uso de los mismos
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CA2964317C (en) 2014-10-14 2021-10-05 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
US20160130324A1 (en) * 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
MD20170035A2 (ro) 2014-10-31 2017-09-30 Ngm Biopharmaceuticals Inc Compoziţii şi metode de utilizare pentru tratamentul tulburărilor metabolice
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
CN107106780B (zh) * 2014-12-23 2020-10-16 莫茨制药有限及两合公司 肉毒杆菌毒素预填充式容器
US10556952B2 (en) * 2015-03-30 2020-02-11 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to Fc gamma receptors
JP2016204292A (ja) * 2015-04-21 2016-12-08 国立大学法人 熊本大学 Bmp7変異体とアルブミンとの融合体、及び該融合体を含む腎疾患治療剤
ES2744342T3 (es) * 2015-04-29 2020-02-24 Mediolanum Farm S P A Un receptor quimérico soluble de interleucina 10 y su uso terapéutico
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2016195723A1 (en) * 2015-06-03 2016-12-08 Beller Pharmaceuticals LLC Methods of treatment for conditions mediated by substance p
EA201792561A1 (ru) 2015-06-05 2018-04-30 Новартис Аг Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения
ES2671844B1 (es) * 2015-06-11 2019-03-22 Attwill Medical Solutions Inc Dispositivos médicos, sistemas y métodos que utilizan composiciones de anti-trombina heparina.
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
ES2852002T3 (es) * 2015-07-30 2021-09-10 Endor Tech S L Factor estimulante de colonias para su uso en el tratamiento del cáncer de páncreas o de colon
BR112018002150A2 (pt) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
RU2752530C2 (ru) 2015-08-03 2021-07-29 Новартис Аг Способы лечения расстройств, связанных с fgf21
CN108368521A (zh) * 2015-08-06 2018-08-03 宾夕法尼亚州大学信托人 Glp-1和其在用于治疗代谢疾病的组合物中的用途
US10633428B2 (en) 2015-08-20 2020-04-28 Albumedix Ltd Albumin variants and conjugates
CN107949638B (zh) 2015-09-08 2022-05-13 Jcr制药股份有限公司 新型人血清白蛋白突变体
DK3347377T3 (da) 2015-09-09 2021-05-10 Novartis Ag Tymisk stromal lymfopoietin (TSLP)-bindende antistoffer og fremgangsmåder til anvendelse af antistofferne
AU2016320748B2 (en) 2015-09-09 2019-05-02 Novartis Ag Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies
CN117659160A (zh) * 2015-09-11 2024-03-08 小利兰·斯坦福大学托管委员会 生物相关正交细胞因子/受体对
US10875923B2 (en) 2015-10-30 2020-12-29 Mayo Foundation For Medical Education And Research Antibodies to B7-H1
MX380414B (es) 2015-12-04 2025-03-12 Boehringer Ingelheim Int Polipeptidos biparatopicos que antagonizan la señalizacion wnt en celulas tumorales.
CO2018007151A2 (es) 2015-12-11 2018-09-20 Dyax Corp Inhibidores de calicreína plasmática y usos de los mismos para tratar ataque de angioedema hereditario
JP2019506844A (ja) 2015-12-18 2019-03-14 ノバルティス アーゲー CD32bを標的とする抗体およびその使用方法
WO2017109706A1 (en) 2015-12-22 2017-06-29 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
CA3009001A1 (en) 2016-01-11 2017-07-20 Universitat Zurich Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
EP3851457A1 (en) 2016-01-21 2021-07-21 Novartis AG Multispecific molecules targeting cll-1
CA3012695A1 (en) 2016-02-01 2017-08-10 Bioverativ Therapeutics Inc. Optimized factor viii genes
WO2017159540A1 (ja) * 2016-03-14 2017-09-21 Jcrファーマ株式会社 血清アルブミン-20k成長ホルモン融合タンパク質
CA3018081A1 (en) 2016-03-22 2017-09-28 Bionomics Limited Administration of an anti-lgr5 monoclonal antibody
MY194669A (en) 2016-03-31 2022-12-12 Ngm Biopharmaceuticals Inc Binding Proteins and Methods of use Thereof
CN109071629A (zh) 2016-04-06 2018-12-21 杰特有限公司 治疗动脉粥样硬化的方法
EP3448887A1 (en) 2016-04-27 2019-03-06 Novartis AG Antibodies against growth differentiation factor 15 and uses thereof
KR102419412B1 (ko) 2016-05-18 2022-07-12 베링거 인겔하임 인터내셔날 게엠베하 암 치료용 항-pd1 및 항-lag3 항체
PE20190117A1 (es) 2016-05-24 2019-01-16 Novo Nordisk As Compuestos de mic-1 y usos de estos
EP3471759A1 (en) 2016-06-15 2019-04-24 Novartis AG Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
KR102446476B1 (ko) * 2016-07-08 2022-10-19 체에스엘 베링 렝나우 아게 사람에서의 장기-작용성 인자 ix의 피하 투여
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
EP3493832A1 (en) 2016-08-05 2019-06-12 CSL Behring GmbH Pharmaceutical formulations of c1 esterase inhibitor
CA3034568A1 (en) 2016-08-23 2018-03-01 Csl Behring Gmbh Method of preventing acute attacks of hereditary angioedema associated with c1 esterase inhibitor deficiency
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
CN110337590A (zh) 2016-11-04 2019-10-15 奥胡斯大学 以新生儿Fc受体过表达为特征的肿瘤的识别和治疗
JP2019535834A (ja) * 2016-11-18 2019-12-12 ユニベルシタ デ バルセロナ 感染症及び関連炎症プロセスの処置のためのcd6及びイミペネムの併用療法
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
US12257288B2 (en) 2016-12-02 2025-03-25 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
US12161696B2 (en) 2016-12-02 2024-12-10 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US20200031895A1 (en) 2016-12-16 2020-01-30 Biogen Ma Inc. Stabilized proteolytically activated growth differentiation factor 11
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
EP3559223A1 (en) 2016-12-23 2019-10-30 President and Fellows of Harvard College Gene editing of pcsk9
CN110325550B (zh) 2016-12-23 2024-03-08 诺华股份有限公司 因子xi抗体和使用方法
IL267519B2 (en) 2016-12-23 2025-04-01 Novartis Ag Factor XI/XIA for use in the prevention, treatment, management, or reduction of the risk of stroke or thromboembolism in a patient with end-stage renal disease
US20190382462A1 (en) 2017-01-13 2019-12-19 Pietro P. Sanna Methods and compositions for treating hpa hyperactivity
MA47416A (fr) 2017-01-31 2019-12-11 Bioverativ Therapeutics Inc Protéine de fusion du facteur ix et procédés de fabrication et d'utilisation associés
DK3580237T3 (da) 2017-02-08 2025-06-30 Novartis Ag Fgf21-mimetiske antistoffer og anvendelser deraf
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
EP3612558A1 (en) 2017-04-20 2020-02-26 Novo Nordisk A/S Methods of purification of albumin fusion proteins
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Mic-1化合物及其用途
CN110662762A (zh) 2017-05-24 2020-01-07 诺华股份有限公司 抗体细胞因子移植蛋白和用于治疗癌症的方法
EA201992808A1 (ru) 2017-05-31 2020-05-14 Бёрингер Ингельхайм Интернациональ Гмбх ПОЛИПЕПТИДЫ, ПРЕПЯТСТВУЮЩИЕ ПЕРЕДАЧЕ Wnt СИГНАЛОВ В ОПУХОЛЕВЫХ КЛЕТКАХ
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
US11253579B2 (en) 2017-06-16 2022-02-22 The University Of Chicago Compositions and methods for inducing immune tolerance
IL271160B2 (en) 2017-06-29 2025-05-01 CSL Behring Lengnau AG 21-day regimen of fusion proteins containing factor IX and human albumin for hemophilia preventive therapies and methods thereof
ES2997332T3 (en) 2017-08-04 2025-02-17 Amgen Inc Method of conjugation of cys-mabs
CA3072334A1 (en) 2017-08-09 2019-02-14 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof
EP3684811A2 (en) 2017-08-17 2020-07-29 Massachusetts Institute of Technology Multiple specificity binders of cxc chemokines and uses thereof
IL273185B2 (en) 2017-09-15 2024-10-01 Cedars Sinai Medical Center C1 esterase inhibitors for use in improving organ function in organ transplantation subjects
KR102715492B1 (ko) 2017-10-18 2024-10-11 씨에스엘 리미티드 인간 혈청 알부민 변이체 및 이의 용도
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
WO2019113642A1 (en) 2017-12-15 2019-06-20 Csl Limited Use of a fxiia-inhibitor in the treatment of renal fibrosis and/or chronic kidney disease
WO2019129054A1 (zh) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 三链抗体、其制备方法及其用途
EP3732202A4 (en) 2017-12-28 2022-06-15 Nanjing Legend Biotech Co., Ltd. SINGLE DOMAIN ANTIBODIES AND VARIANTS THEREOF AGAINST TIGIT
US11246908B2 (en) * 2018-01-10 2022-02-15 The Johns Hopkins University Compositions comprising albumin-FMS-like tyrosine kinase 3 ligand fusion proteins and uses thereof
KR102839330B1 (ko) 2018-01-15 2025-07-30 난징 레전드 바이오테크 씨오., 엘티디. Pd-1에 대한 단일-도메인 항체 및 이의 변이체
MX2020008152A (es) 2018-02-01 2020-11-24 Bioverativ Therapeutics Inc Uso de vectores lentivirales que expresan el factor viii.
CN112020519A (zh) 2018-03-13 2020-12-01 酵活有限公司 抗her2双互补位抗体-药物偶联物及使用方法
EP3765055B9 (en) * 2018-03-13 2023-09-27 Sepsia Therapeutics, S.L. Bacterial-binding peptides for treatment of infectious diseases and related inflammatory processes
EA202092316A1 (ru) 2018-03-28 2021-05-25 Бристол-Маерс Сквибб Компани Слитые белки интерлейкина-2/альфа-рецептора интерлейкина-2 и способы применения
KR20200138720A (ko) 2018-03-30 2020-12-10 난징 레전드 바이오테크 씨오., 엘티디. Lag-3에 대한 단일-도메인 항체 및 이의 용도
KR102119197B1 (ko) * 2018-04-23 2020-06-05 주식회사 엘베이스 세포에서의 자가포식작용 억제용 조성물, 및 이를 포함하는 종양성 질환의 예방 또는 치료용, 또는 항암제 내성 억제용 약학적 조성물
CA3099404A1 (en) 2018-05-09 2019-11-14 The University Of Chicago Compositions and methods concerning immune tolerance
EP3794023A1 (en) 2018-05-14 2021-03-24 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
EP3794024B1 (en) 2018-05-14 2023-05-10 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
EP4585260A3 (en) 2018-05-18 2025-08-13 Bioverativ Therapeutics Inc. Methods of treating hemophilia a
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
SG11202010579XA (en) 2018-06-01 2020-12-30 Novartis Ag Binding molecules against bcma and uses thereof
EP3807321A4 (en) 2018-06-18 2022-03-02 Anwita Biosciences, Inc. ANTI-MESOTHELIN CONSTRUCTIONS AND ASSOCIATED USES
US12226451B2 (en) 2018-07-03 2025-02-18 Bristol-Myers Squibb Company FGF-21 formulations
MX2021001599A (es) 2018-08-09 2021-07-02 Bioverativ Therapeutics Inc Moleculas de acido nucleico y sus usos para la terapia genica no viral.
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
PL3844189T3 (pl) 2018-08-31 2025-03-31 Regeneron Pharmaceuticals, Inc. Strategia dawkowania, która łagodzi zespół uwalniania cytokin, dla przeciwciał dwuswoistych cd3/cd20
JP2022500427A (ja) * 2018-09-17 2022-01-04 国立大学法人京都大学 肝傷害又は肝不全の処置のための抗c5剤の投与
CA3112989A1 (en) 2018-09-27 2020-04-02 Xilio Development, Inc. Masked cytokine polypeptides
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
BR112021008200A2 (pt) * 2018-10-29 2021-12-14 Spin Therapeutics Llc Composições e métodos para distúrbios de alfa-1-antitripsina
US12264189B2 (en) 2018-10-31 2025-04-01 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
GB201818477D0 (en) 2018-11-13 2018-12-26 Emstopa Ltd Tissue plasminogen activator antibodies and method of use thereof
WO2020109978A1 (en) 2018-11-26 2020-06-04 Novartis Ag Lpl-gpihbp1 fusion polypeptides
KR20210100661A (ko) 2018-12-06 2021-08-17 바이오버라티브 테라퓨틱스 인크. 인자 ix를 발현하는 렌티바이러스 벡터의 용도
WO2020198075A2 (en) 2019-03-22 2020-10-01 Reflexion Pharmaceuticals, Inc. Multivalent d-peptidic compounds for target proteins
KR20220029545A (ko) 2019-03-22 2022-03-08 리플렉시온 파마슈티컬스, 인크. Vegf에 대한 d-펩티드성 화합물
US20220169706A1 (en) 2019-03-28 2022-06-02 Danisco Us Inc Engineered antibodies
CA3133803A1 (en) 2019-04-11 2020-10-15 Angion Biomedica Corp. Solid forms of (e)-3-[2-(2-thienyl)vinyl]-1h-pyrazole
SG11202112541RA (en) 2019-05-14 2021-12-30 Werewolf Therapeutics Inc Separation moieties and methods and use thereof
PH12021552916A1 (en) 2019-05-21 2022-04-04 Novartis Ag Cd19 binding molecules and uses thereof
EP3972993A1 (en) 2019-05-21 2022-03-30 Novartis AG Variant cd58 domains and uses thereof
CA3141492A1 (en) 2019-05-24 2020-12-03 Sanofi Methods for treating systemic sclerosis
US20220387608A1 (en) 2019-06-18 2022-12-08 Bayer Aktiengesellschaft Adrenomedullin-analogues for long-term stabilization and their use
US20230220048A1 (en) 2019-09-06 2023-07-13 Novartis Ag Therapeutic fusion proteins
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與entpd2抗體之組合療法
EP4038182A1 (en) 2019-09-30 2022-08-10 Bioverativ Therapeutics Inc. Lentiviral vector formulations
KR20220083784A (ko) 2019-10-17 2022-06-20 제이씨알 파마 가부시키가이샤 혈청 알부민과 성장 호르몬의 융합 단백질의 제조 방법
US20220378882A1 (en) 2019-10-30 2022-12-01 Jcr Pharmaceuticals Co., Ltd. Aqueous pharmaceutical composition containing fusion protein of serum albumin and growth hormone
KR20220101147A (ko) 2019-11-14 2022-07-19 웨어울프 세라퓨틱스, 인크. 활성화가능한 사이토카인 폴리펩티드 및 이의 사용 방법
EP4069200A1 (en) 2019-12-04 2022-10-12 Albumedix Ltd Methods and compositions produced thereby
CA3164233A1 (en) 2019-12-13 2021-06-17 Synthekine, Inc. Il-2 orthologs and methods of use
US20210181200A1 (en) * 2019-12-17 2021-06-17 Women's College Hospital Ovarian cancer biomarker and methods of using same
EP4081241A4 (en) 2019-12-24 2024-05-01 Juvena Therapeutics, Inc. REGENERATIVE POLYPEPTIDES AND THEIR USES
US20230203191A1 (en) 2020-03-30 2023-06-29 Danisco Us Inc Engineered antibodies
GB2623891B (en) 2020-04-09 2024-10-23 Verve Therapeutics Inc Base editing of ANGPTL3 and methods of using same for treatment of disease
CA3180665A1 (en) 2020-05-19 2021-11-25 Boehringer Ingelheim International Gmbh Binding molecules for the treatment of cancer
CA3182800A1 (en) 2020-06-14 2021-12-23 Vertex Pharmaceuticals Inc. Complement factor i-related compositions and methods
AU2021297965A1 (en) 2020-06-24 2023-02-23 Bioverativ Therapeutics Inc. Methods for the removal of free factor VIII from preparations of lentiviral vectors modified to express said protein
EP4232476A2 (en) 2020-10-21 2023-08-30 Boehringer Ingelheim International GmbH Agonistic trkb binding molecules for the treatment of eye diseases
JP2023547479A (ja) * 2020-10-30 2023-11-10 シェンチェン、プロトゲン、リミテッド 疾患の治療におけるヒト血清アルブミンの使用
MX2023005353A (es) 2020-11-06 2023-05-22 Novartis Ag Moleculas de union a cd19 y usos de las mismas.
KR20230113581A (ko) 2020-11-25 2023-07-31 실리오 디벨럽먼트, 인크. 종양 특이적 절단성 링커
WO2022166720A1 (zh) * 2021-02-05 2022-08-11 华南理工大学 基于血清白蛋白的融合蛋白、纳米组装体及其制备方法和应用
US20240228593A9 (en) 2021-02-19 2024-07-11 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services SINGLE DOMAIN ANTIBODIES THAT NEUTRALIZE SARS-CoV-2
WO2022263507A1 (en) 2021-06-17 2022-12-22 Boehringer Ingelheim International Gmbh Novel tri-specific binding molecules
AU2022298470A1 (en) 2021-06-21 2024-02-01 Juvena Therapeutics, Inc. Regenerative polypeptides and uses thereof
CN114133458B (zh) * 2021-12-08 2023-11-14 福州大学 一种在人血清白蛋白内部融合多肽的方法
PE20251172A1 (es) 2022-04-26 2025-04-23 Novartis Ag Anticuerpos multiespecificos que se dirigen a il-13 e il-18
MA71446A (fr) 2022-07-15 2025-04-30 Boehringer Ingelheim International Gmbh Molécules de liaison pour le traitement du cancer
EP4554619A1 (en) 2022-07-15 2025-05-21 Danisco US Inc. Methods for producing monoclonal antibodies
EP4605077A1 (en) 2022-10-18 2025-08-27 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
WO2024130158A1 (en) 2022-12-16 2024-06-20 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease
TW202440624A (zh) * 2022-12-20 2024-10-16 澳大利亞商杰特創新股份有限公司 FcRn拮抗劑及其用途
EP4389762A1 (en) 2022-12-23 2024-06-26 Ospedale San Raffaele S.r.l. Inhibitors of dux4 activity and their use in therapy.
WO2024178305A1 (en) 2023-02-24 2024-08-29 Modernatx, Inc. Compositions of mrna-encoded il-15 fusion proteins and methods of use thereof for treating cancer
EP4442251A1 (en) 2023-04-05 2024-10-09 Albumedix Ltd Formulations and uses thereof
WO2025034806A1 (en) 2023-08-08 2025-02-13 Wisconsin Alumni Research Foundation Single-domain antibodies and variants thereof against fibroblast activation protein
WO2025072888A2 (en) 2023-09-28 2025-04-03 Novavax, Inc. Anti-sars-cov-2 spike (s) antibodies and their use in treating covid-19

Family Cites Families (702)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5625041A (en) * 1990-09-12 1997-04-29 Delta Biotechnology Limited Purification of proteins
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE2449885C3 (de) * 1974-10-21 1980-04-30 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verfahren zur Herstellung von chemisch modifizierten haltbaren Hämoglobinpräparaten sowie das nach diesem Verfahren hergestellte modifizierte Hämoglobinpräparat
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4264731A (en) * 1977-05-27 1981-04-28 The Regents Of The University Of California DNA Joining method
US4440859A (en) * 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4363877B1 (en) 1977-09-23 1998-05-26 Univ California Recombinant dna transfer vectors
US4283489A (en) 1977-09-23 1981-08-11 The Regents Of The University Of California Purification of nucleotide sequences suitable for expression in bacteria
US4407948A (en) 1977-09-23 1983-10-04 The Regents Of The University Of California Purification of nucleotide sequences suitable for expression in bacteria
US4366246A (en) 1977-11-08 1982-12-28 Genentech, Inc. Method for microbial polypeptide expression
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4447538A (en) * 1978-04-19 1984-05-08 Regents Of The University Of California Microorganism containing gene for human chorionic somatomammotropin
US4652525A (en) * 1978-04-19 1987-03-24 The Regents Of The University Of California Recombinant bacterial plasmids containing the coding sequences of insulin genes
US5514567A (en) * 1979-01-30 1996-05-07 Juridical Foundation, Japanese Foundation For Cancer Research DNA and recombinant plasmid
US5326859A (en) 1979-10-30 1994-07-05 Juridical Foundation, Japanese Foundation For Cancer Research DNA and recombinant plasmid
US4342832A (en) 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
AU538665B2 (en) 1979-10-30 1984-08-23 Juridical Foundation, Japanese Foundation For Cancer Research Human interferon dna
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
NZ195980A (en) 1980-01-08 1984-10-19 Biogen Nv Dna sequences,recombinant dna molecules and processes for producing leukocyte interferon-like polypeptides;pharmaceutical and veterinary compositions
ATE56471T1 (de) 1980-04-03 1990-09-15 Biogen Inc Dns-sequenzen, rekombinante dns-molekuele und verfahren zur herstellung von dem menschlichen fibroblast-interferon.
DE3023787A1 (de) 1980-06-25 1982-01-21 Studiengesellschaft Kohle mbH, 4330 Mülheim Verfahren zur erhoehung der inkorporation und der expression von genetischem material in die kerne von intakten zellen mit hilfe von liposomen
US6610830B1 (en) 1980-07-01 2003-08-26 Hoffman-La Roche Inc. Microbial production of mature human leukocyte interferons
FR2490675B1 (fr) 1980-09-25 1985-11-15 Genentech Inc Production microbienne d'interferon de fibroplaste humain
US4456748A (en) 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
ATE12348T1 (de) 1980-11-10 1985-04-15 Gersonde Klaus Prof Dr Verfahren zur herstellung von lipid-vesikeln durch ultraschallbehandlung, anwendung des verfahrens und vorrichtung zur durchfuehrung des verfahrens.
WO1982002715A1 (fr) 1981-02-04 1982-08-19 Sugano Haruo Gene d'interferon (beta)humain
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
JPS57149228A (en) 1981-03-11 1982-09-14 Ajinomoto Co Inc Novel erythropoietin and its preparation
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
CA1204682A (en) 1981-06-19 1986-05-20 Saran A. Narang Adaptors, and synthesis and cloning of proinsulin genes
US4792602A (en) 1981-06-19 1988-12-20 Cornell Research Foundation, Inc. Adaptors, and synthesis and cloning of proinsulin genes
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
IL66614A (en) 1981-08-28 1985-09-29 Genentech Inc Method of constructing a dna sequence encoding a polypeptide,microbial production of human serum albumin,and pharmaceutical compositions comprising it
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
EP0079739A3 (en) 1981-11-12 1984-08-08 The Upjohn Company Albumin-based nucleotides, their replication and use, and plasmids for use therein
EP0091527A3 (en) 1981-12-14 1984-07-25 The President And Fellows Of Harvard College Dna sequences, recombinant dna molecules and processes for producing human serum albumin-like polypeptides
JPS58107298A (ja) 1981-12-21 1983-06-25 Yoshitsuka Seiki:Kk 粉末成形プレスにおけるシエ−カ−カムの位相調整装置
JPS58118008A (ja) 1982-01-06 1983-07-13 Nec Corp デ−タ処理装置
EP0098876A1 (en) 1982-01-19 1984-01-25 Cetus Corporation Multiclass hybrid interferons
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4450103A (en) * 1982-03-01 1984-05-22 Cetus Corporation Process for recovering human IFN-β from a transformed microorganism
US4775622A (en) 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
US4670393A (en) 1982-03-22 1987-06-02 Genentech, Inc. DNA vectors encoding a novel human growth hormone-variant protein
CA1341562C (en) 1982-03-31 2007-11-27 Tadatsugu Taniguchi Gene coded for interleukin-2 polypeptide, recombinant dna carrying the said gene, a living cell line possessing the recombinant dna, and method for producing interleukin-2 using the said cell
DE3377363D1 (en) 1982-03-31 1988-08-18 Ajinomoto Kk Gene coding for interleukin-2 polypeptide, recombinant dna carrying said gene, cell lines possessing the recombinant dna,and method for producing interleukin-2 using said cells
US5824330A (en) 1982-04-20 1998-10-20 Sloan-Kettering Institute For Cancer Research Highly purified interleukin-2 and method
US4778879A (en) 1982-04-20 1988-10-18 Sloan-Kettering Institute For Cancer Research Highly purified human interleukin 2 and method
US4925919A (en) * 1984-04-25 1990-05-15 Roland Mertelsmann Purified interleukin 2
US4499188A (en) * 1982-05-05 1985-02-12 Cetus Corporation Bacterial production of heterologous polypeptides under the control of a repressible promoter-operator
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
JPS5945835U (ja) 1982-09-16 1984-03-27 株式会社東芝 回路しや断器の消弧装置
US4490289A (en) 1982-09-16 1984-12-25 Hoffmann-La Roche Inc. Homogeneous human interleukin 2
US4992271A (en) 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
US4462940A (en) * 1982-09-23 1984-07-31 Cetus Corporation Process for the recovery of human β-interferon-like polypeptides
IE56026B1 (en) 1982-10-19 1991-03-27 Cetus Corp Cysteine-depleted muteins of biologically active proteins
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4966843A (en) * 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
EP0116201B1 (en) 1983-01-12 1992-04-22 Chiron Corporation Secretory expression in eukaryotes
US4840934A (en) * 1983-01-25 1989-06-20 Eleanor Roosevelt Institute For Cancer Research, Inc. Therapeutic method using T cell growth factor
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
DK172738B1 (da) 1983-04-07 1999-06-21 Chiron Corp Fremgangsmåde til at udtrykke modent insulin og DNA-struktur til anvendelse ved fremgangsmåden
US5015575A (en) * 1983-04-07 1991-05-14 Chiron Corporation Hybrid DNA synthesis of insulin
US4914026A (en) * 1983-04-07 1990-04-03 Chiron Corporation Alpha factor leader sequence directed secretion of insulin
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
WO1984004330A1 (en) 1983-04-22 1984-11-08 Amgen Secretion of exogenous polypeptides from yeast
NZ207926A (en) 1983-04-25 1988-04-29 Genentech Inc Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
US5010003A (en) * 1983-04-25 1991-04-23 Genentech, Inc. Use of yeast homologous signals to secrete heterologous proteins
CA1196863A (en) * 1983-06-08 1985-11-19 Mattheus F.A. Goosen Slow release injectable insulin composition
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4576813A (en) 1983-07-05 1986-03-18 Monsanto Company Heat recovery from concentrated sulfuric acid
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
JPS6087792A (ja) 1983-09-23 1985-05-17 ジェネックス・コーポレイション 雑種制御領域
DE3483949D1 (de) 1983-09-26 1991-02-21 Udo Dr Med Ehrenfeld Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr.
US4518564A (en) * 1983-10-03 1985-05-21 Jeneric Industries, Inc. Gallium and silver free, palladium based dental alloys for porcelain-fused-to-metal restorations
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
JPS60115528A (ja) 1983-11-28 1985-06-22 Takeda Chem Ind Ltd ヒトインタ―ロイキン―2蛋白質を含有する抗腫瘍用または免疫機能低下疾患治療用組成物
GB8334102D0 (en) 1983-12-21 1984-02-01 Searle & Co Interferons with cysteine pattern
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4855238A (en) 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
GB8334261D0 (en) 1983-12-22 1984-02-01 Bass Plc Fermentation processes
JPS60136596A (ja) 1983-12-26 1985-07-20 Suntory Ltd ペプチド及びこれを有効成分とする利尿剤
IT1185503B (it) 1984-01-11 1987-11-12 Univ New York Cloni di odna di eritropietina umana
US4908434A (en) * 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Process for preparing purified interleukin-2
US4908433A (en) * 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Uses of interleukin-2
CA1213537A (en) 1984-05-01 1986-11-04 Canadian Patents And Development Limited - Societe Canadienne Des Brevets Et D'exploitation Limitee Polypeptide expression method
FR2564106B1 (fr) * 1984-05-09 1988-04-22 Transgene Sa Vecteurs d'expression du facteur ix, cellules transformees par ces vecteurs et procede de preparation du facteur ix.
DK58285D0 (da) 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
EP0172619A1 (en) 1984-06-20 1986-02-26 Takeda Chemical Industries, Ltd. Novel transformant and use thereof
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US5908763A (en) 1984-07-06 1999-06-01 Novartis Corporation DNA encoding GM-CSF and a method of producing GM-CSF protein
JPS61227526A (ja) 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4734491A (en) 1984-08-31 1988-03-29 University Patents, Inc. DNA sequences encoding hybrid lymphoblastoid-leukocyte human interferons
US4716217A (en) 1984-08-31 1987-12-29 University Patents, Inc. Hybrid lymphoblastoid-leukocyte human interferons
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
IL77081A (en) 1984-12-04 1999-10-28 Genetics Inst Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4677195A (en) 1985-01-11 1987-06-30 Genetics Institute, Inc. Method for the purification of erythropoietin and erythropoietin compositions
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
GB8504099D0 (en) * 1985-02-18 1985-03-20 Wellcome Found Physiologically active substances
DK129385A (da) 1985-03-22 1986-09-23 Novo Industri As Peptider og fremstilling deraf
FR2579224B1 (fr) * 1985-03-25 1987-05-22 Genetica Procede de preparation microbiologique de la serum-albumine humaine
DE3679343D1 (de) 1985-03-28 1991-06-27 Chiron Corp Expression durch verwendung von fusionsgenen fuer proteinproduktion.
US4751180A (en) * 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
DE3668186D1 (de) 1985-04-01 1990-02-15 Celltech Ltd Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
GB8510219D0 (en) 1985-04-22 1985-05-30 Bass Plc Isolation of fermentation products
KR870000428A (ko) 1985-06-17 1987-02-18 . 인체혈청 알부민의 제조방법
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5102872A (en) * 1985-09-20 1992-04-07 Cetus Corporation Controlled-release formulations of interleukin-2
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
JPH0618778B2 (ja) 1985-10-04 1994-03-16 中外製薬株式会社 白血球減少症治療剤
JPS6296086A (ja) 1985-10-21 1987-05-02 Agency Of Ind Science & Technol 複合プラスミド
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
CA1295563C (en) 1985-11-01 1992-02-11 Robert T. Garvin Production of active proteins containing cystine residues
US5576195A (en) 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
AU606320B2 (en) 1985-11-01 1991-02-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US5641663A (en) * 1985-11-06 1997-06-24 Cangene Corporation Expression system for the secretion of bioactive human granulocyte macrophage colony stimulating factor (GM-CSF) and other heterologous proteins from steptomyces
CA1295566C (en) 1987-07-21 1992-02-11 Robert T. Garvin Characterization and structure of genes for protease a and protease b from streptomyces griseus
JPH0780930B2 (ja) 1985-12-26 1995-08-30 三井石油化学工業株式会社 α−オレフインの重合方法
JPH0645551B2 (ja) 1986-01-07 1994-06-15 塩野義製薬株式会社 インタ−ロイキン−2組成物
ATE74272T1 (de) 1986-01-22 1992-04-15 Chugai Pharmaceutical Co Ltd Pharmazeutischer stoff fuer die behandlung von myelogener leukaemie.
ATE65403T1 (de) 1986-01-22 1991-08-15 Chugai Pharmaceutical Co Ltd Pharmazeutischer stoff fuer die foerderung der wiederherstellung der haematopoietischen faehigkeit.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
FR2594846B1 (fr) * 1986-02-21 1989-10-20 Genetica Procede de preparation de la serum albumine humaine mature
EP0237019A3 (en) 1986-03-14 1988-03-09 Toray Industries, Inc. Interferon conjugate and production thereof using recombinant gene
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IT1203758B (it) 1986-03-27 1989-02-23 Univ Roma Vettori di clonazione e di espressione di geni eterologhi in lieviti e lieviti trasformati con tali vettori
DK179286D0 (da) 1986-04-18 1986-04-18 Nordisk Gentofte Insulinpraeparat
US4765980A (en) * 1986-04-28 1988-08-23 International Minerals & Chemical Corp. Stabilized porcine growth hormone
US4859609A (en) 1986-04-30 1989-08-22 Genentech, Inc. Novel receptors for efficient determination of ligands and their antagonists or agonists
US5028422A (en) * 1986-05-27 1991-07-02 Schering Corporation Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
US5985599A (en) 1986-05-29 1999-11-16 The Austin Research Institute FC receptor for immunoglobulin
IT1204400B (it) * 1986-06-20 1989-03-01 Sclavo Spa Composizioni farmaceutiche contenente una calcitonina
GB8615701D0 (en) 1986-06-27 1986-08-06 Delta Biotechnology Ltd Stable gene integration vector
IT1196484B (it) 1986-07-11 1988-11-16 Sclavo Spa Vettore ad espressione e secrezione in lieviti,utile per la preparazione di proteine eterologhe
GR871067B (en) 1986-07-18 1987-11-19 Chugai Pharmaceutical Co Ltd Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor
US4857467A (en) 1986-07-23 1989-08-15 Phillips Petroleum Company Carbon and energy source markers for transformation of strains of the genes Pichia
US4801575A (en) * 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5002764A (en) * 1986-08-12 1991-03-26 Schering Corporation Treatment of actinic keratoses with alpha2 interferon
GB8620926D0 (en) 1986-08-29 1986-10-08 Delta Biotechnology Ltd Yeast promoter
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
US5508031A (en) * 1986-11-21 1996-04-16 Cetus Oncology Corporation Method for treating biological damage using a free-radial scavenger and interleukin-2
US4835260A (en) * 1987-03-20 1989-05-30 Genetics Institute, Inc. Erythropoietin composition
FI885224L (fi) 1987-03-23 1988-11-11 Amgen Inc Renad tillvaextfaktor som haerstammar fraon blodplaettar och foerfaranden foer dess rening.
HU213344B (en) * 1987-04-09 1997-05-28 Delta Biotechnology Ltd Process for producing of stable dezintegrating plasmid-vectors
EP0682110A1 (en) 1987-04-22 1995-11-15 Chiron Corporation Recombinant DNA encoding PDGF A-chain polypeptides
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4994560A (en) 1987-06-24 1991-02-19 The Dow Chemical Company Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
US5489425A (en) 1987-06-24 1996-02-06 The Dow Chemical Company Functionalized polyamine chelants
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
ZA885536B (en) 1987-07-28 1989-04-26 Gist Brocades Nv Kluyveromyces as a host strain
JPH0622784Y2 (ja) 1987-08-04 1994-06-15 東洋シヤッター株式会社 オ−バ−ドア用可動中柱の高さ調整装置
JP2627899B2 (ja) 1987-08-19 1997-07-09 株式会社 ビタミン研究所 遺伝子封入リポソームの製法
SE459586B (sv) 1987-09-14 1989-07-17 Mta Szegedi Biolog Koezponti Strukturgen som kodar foer autentiskt humant serum albumin och foerfarande foer dess framstaellning
NZ226414A (en) 1987-10-02 1992-07-28 Genentech Inc Cd4 peptide adhesion variants and their preparation and use
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
JPH0811074B2 (ja) 1987-10-30 1996-02-07 財団法人化学及血清療法研究所 プレアルブミンをコードする遺伝子を組込んだ組換えプラスミドおよびこれを用いたプレアルブミンの製法
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
GB8726953D0 (en) 1987-11-18 1987-12-23 Delta Biotechnology Ltd Yeast expression system
JP2791418B2 (ja) * 1987-12-02 1998-08-27 株式会社ミドリ十字 異種蛋白質の製造方法、組換えdna、形質転換体
US5282856A (en) 1987-12-22 1994-02-01 Ledergerber Walter J Implantable prosthetic device
PT89484B (pt) 1988-01-22 1994-03-31 Gen Hospital Corp Genes clonados codificadores de proteinas de fusao ig-cd4 e sua utilizacao
JPH01240191A (ja) * 1988-02-16 1989-09-25 Green Cross Corp:The 酵母で機能する新規シグナルペプチドおよびこれを用いた異種蛋白質の分泌発現
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンaの製造方法
US4999339A (en) * 1988-03-28 1991-03-12 Cetus Corporation Combination therapy of IL-2 and DTIC for the treatment of melanoma
US5066489A (en) 1988-03-28 1991-11-19 Cetus Corporation Combination therapy of IL-2 and DTIC for the treatment of melanoma
US5061488A (en) 1988-04-15 1991-10-29 The United States Of America As Represented Department Of Health & Human Services Flavone-8-acetic acid and interleukin-2 for cancer therapy
US5096707A (en) * 1988-04-15 1992-03-17 The United States Of America As Represented By The Department Of Health And Human Services Flavone-8-acetic acid and interleukin-2 in a method of treating certain cancers
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
IL89992A0 (en) 1988-04-25 1989-12-15 Phillips Petroleum Co Expression of human serum albumin in methylotrophic yeasts
IL89989A0 (en) 1988-04-25 1989-12-15 Phillips Petroleum Co Expression of human interleukin-2 in methylotrophic yeasts
US5126129A (en) * 1988-05-23 1992-06-30 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Cancer therapy using interleukin-2 and flavone compounds
DE58906966D1 (de) 1988-06-23 1994-03-24 Hoechst Ag Mini-Proinsulin, seine Herstellung und Verwendung.
PT90959B (pt) 1988-06-24 1995-05-04 Dow Chemical Co Processo para a preparacao de quelantes macrociclicos bifuncionais, de seus complexos e seus conjugados com anticorpos
EP0353450B1 (en) 1988-06-24 1995-03-29 The Dow Chemical Company Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates
US5756065A (en) 1988-06-24 1998-05-26 The Dow Chemical Company Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents
US5274119A (en) 1988-07-01 1993-12-28 The Dow Chemical Company Vicinal diols
HU213571B (en) 1988-07-23 1997-08-28 Delta Biotechnology Ltd Process for producing peptides and dna sequences
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
FR2635115B1 (fr) 1988-08-05 1992-04-03 Rhone Poulenc Sante Procede de preparation de la serum albumine humaine a partir d'une levure
WO1990001540A1 (en) 1988-08-11 1990-02-22 California Biotechnology Inc. Method for stabilizing heterologous protein expression and vectors for use therein
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
WO1990002809A1 (en) 1988-09-02 1990-03-22 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5260202A (en) 1988-09-07 1993-11-09 Delta Biotechnology Limited Fermentation method
JPH02227079A (ja) 1988-10-06 1990-09-10 Tonen Corp ヒト血清アルブミン断片
US5298243A (en) 1988-10-20 1994-03-29 Denki Kagaku Kogyo Kabushiki Kaisha Colony stimulating factor-gelatin conjugate
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5759802A (en) 1988-10-26 1998-06-02 Tonen Corporation Production of human serum alubumin A
JPH02117384A (ja) 1988-10-26 1990-05-01 Tonen Corp 酵母宿主によるヒト血清アルブミンaの製造
DE68929151T2 (de) 1988-10-28 2000-07-20 Genentech, Inc. Verfahren zum nachweis von aktiven domänen und aminosäureresten in polypeptiden und hormonvarianten
US5342604A (en) 1988-10-31 1994-08-30 The Dow Chemical Company Complexes possessing ortho ligating functionality
US5696239A (en) 1988-10-31 1997-12-09 The Dow Chemical Company Conjugates possessing ortho ligating functionality and complexes thereof
US5256410A (en) 1988-12-01 1993-10-26 Schering Corporation Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
US4975271A (en) 1988-12-19 1990-12-04 Vipont Pharmaceutical, Inc. Muscosal delivery systems for treatment of periodontal disease
WO1990006952A1 (en) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
DK105489D0 (da) * 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5705363A (en) * 1989-03-02 1998-01-06 The Women's Research Institute Recombinant production of human interferon τ polypeptides and nucleic acids
WO1990011296A1 (en) 1989-03-20 1990-10-04 The General Hospital Corporation Insulinotropic hormone
JP3250802B2 (ja) 1989-03-21 2002-01-28 バイカル・インコーポレイテッド 脊椎動物における外因性ポリヌクレオチド配列の発現
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5231020A (en) 1989-03-30 1993-07-27 Dna Plant Technology Corporation Genetic engineering of novel plant phenotypes
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
DK0392300T3 (da) * 1989-04-11 1992-09-28 Boehringer Ingelheim Int Anvendelse af lægemidler, der indeholder mindst et cytokin, til systemisk behandling af præneoplastiske læsioner
EP0395918A3 (en) 1989-04-13 1991-10-23 Vascular Laboratory, Inc. Plasminogen activator complex of pure pro-urokinase covalently bound by a disulfide bridge to human serum albumin
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
GB8909916D0 (en) * 1989-04-29 1989-06-14 Delta Biotechnology Ltd Polypeptides
US5766883A (en) * 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
CA2055441C (en) 1989-05-19 2003-01-07 Robert M. Hudziak Her2 extracellular domain
CA2017379C (en) 1989-05-24 2002-06-25 Kenneth A. Thomas, Jr. Purification and characterization of a glioma-derived growth factor
US5808003A (en) 1989-05-26 1998-09-15 Perimmune Holdings, Inc. Polyaminocarboxylate chelators
US5330971A (en) * 1989-06-09 1994-07-19 Gropep Pty. Ltd. Growth hormone fusion proteins, methods of production, and methods of treatment
JPH0327320A (ja) 1989-06-26 1991-02-05 Ajinomoto Co Inc ヒトb細胞分化因子医薬組成物
DK0479909T3 (da) 1989-06-29 1997-04-07 Medarex Inc Bispecifikke reagenser til AIDS-behandling
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
DE3924746A1 (de) * 1989-07-26 1991-01-31 Behringwerke Ag Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
CU22222A1 (es) 1989-08-03 1995-01-31 Cigb Procedimiento para la expresion de proteinas heterologicas producidas de forma fusionada en escherichia coli, su uso, vectores de expresion y cepas recombinantes
GB8927480D0 (en) 1989-12-05 1990-02-07 Delta Biotechnology Ltd Mutant fungal strain detection and new promoter
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
DK0489116T3 (da) 1989-08-22 1994-05-02 Immunex Corp Fusionsproteiner omfattende GM-CSF og IL-3
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US6063373A (en) * 1989-09-19 2000-05-16 Maxim Pharmaceuticals, Inc. Enhanced activation of NK cells using an NK cell activator and a hydrogen peroxide scavenger or inhibitor
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
IE66494B1 (en) 1989-09-26 1996-01-10 Immunex Corp Granulocyte-colony stimulating factor receptors
WO1991005052A1 (en) 1989-09-28 1991-04-18 Leningradsky Gosudarstvenny Universitet Method for obtaining a polypeptide with human-interleukin-2 activity, secreted by yeast cells, saccharomyces cerevisiae
WO1991005058A1 (en) 1989-10-05 1991-04-18 Glenn Kawasaki Cell-free synthesis and isolation of novel genes and polypeptides
FR2653020B1 (fr) 1989-10-17 1993-03-26 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour la preparation de compositions pharmaceutiques destinees au traitement des leucemies.
US5667986A (en) 1989-10-18 1997-09-16 Delta Biotechnology Limited Yeast promoter for expressing heterologous polypeptides
GB8924021D0 (en) 1989-10-25 1989-12-13 Celltech Ltd Recombinant dna method and vectors for the use therein
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
AU625013B2 (en) 1989-11-03 1992-06-25 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5580560A (en) * 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
US5173408A (en) 1989-11-13 1992-12-22 Lange Louis George Iii Mammalian pancreatic cholesterol esterase
DK608589D0 (da) 1989-12-01 1989-12-01 Holm Arne Kemisk fremgangsmaade
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5116944A (en) * 1989-12-29 1992-05-26 Neorx Corporation Conjugates having improved characteristics for in vivo administration
JPH03201987A (ja) 1989-12-29 1991-09-03 Tonen Corp ヒト血清アルブミン断片
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
ES2113879T3 (es) 1990-01-24 1998-05-16 Douglas I Buckley Analogos de glp-1 utiles para el tratamiento de diabetes.
DK0439442T3 (da) * 1990-01-25 1996-07-08 Univ Washington Faktor X-LACI-hybridprotein
JPH04211375A (ja) 1990-02-05 1992-08-03 Ajinomoto Co Inc 合成遺伝子及びそれを用いたヒト血清アルブミンの製造法
US5747334A (en) 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
US5208018A (en) * 1990-03-19 1993-05-04 Brigham And Women's Hospital Treatment of cachexia with interleukin 2
FR2660863B1 (fr) * 1990-04-17 1994-01-21 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour preparer une composition pharmaceutique destinee au traitement de cancers primitifs de la plevre.
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
GB9013017D0 (en) 1990-06-11 1990-08-01 Mars Uk Ltd Compounds
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992001055A1 (de) 1990-07-10 1992-01-23 Boehringer Ingelheim International Gmbh O-glycosyliertes ifn-alpha
US5225341A (en) 1990-07-19 1993-07-06 The Regents Of The University Of California Biologically safe plant transformation system using a ds transposon
US5202239A (en) * 1990-08-07 1993-04-13 Scios Nova Inc. Expression of recombinant polypeptides with improved purification
US5071872A (en) 1990-08-14 1991-12-10 The Ohio State University Research Foundation Method for improving interleukin-2 activity using aci-reductone compounds
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5391183A (en) * 1990-09-21 1995-02-21 Datascope Investment Corp Device and method sealing puncture wounds
IT1242149B (it) 1990-09-27 1994-02-16 Consiglio Nazionale Ricerche Sequenza di nucleotidi codificante per una proteina umana con proprieta' regolative dell'angiogenesi
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DE69130709T3 (de) 1990-10-05 2005-12-22 Celldex Therapeutics, Inc. Gezielte immunostimulierung mit bispezifischen stoffen
JPH07108232B2 (ja) 1990-10-09 1995-11-22 エム・ディ・リサーチ株式会社 ペプチド又は蛋白質の製造方法
JPH0638771Y2 (ja) 1990-10-26 1994-10-12 株式会社カンセイ エアバック制御装置
WO1992008802A1 (en) 1990-10-29 1992-05-29 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
FR2668368B1 (fr) 1990-10-30 1995-03-10 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour preparer une composition pharmaceutique destinee au traitement des tumeurs malignes epitheliales.
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
JPH0638771A (ja) 1990-10-31 1994-02-15 Tonen Corp ヒトプロテインジスルフィドイソメラーゼ遺伝子の発現方法および該遺伝子との共発現によるポリペプチドの製造方法
US5353535A (en) 1990-11-05 1994-10-11 Plumly George W Floor type advertising apparatus
US5830452A (en) 1990-11-20 1998-11-03 Chiron Corporation Method for enhancing the anti-tumor therapeutic index of interleukin-2
US5378823A (en) 1990-11-29 1995-01-03 Institut National De La Recherche Agronomique-I.N.R.A. Nucleic acids encoding type I interferon variants
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5272080A (en) * 1991-02-19 1993-12-21 Pharmavene, Inc. Production of butyrylcholinesterase
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5272070A (en) * 1991-03-08 1993-12-21 Board Of Regents, The University Of Texas System Method for the preparation of cell lines producing Man3 GlcNac 2 asparagine-linked gylcans and cell lines produced thereby
CA2062659A1 (en) 1991-03-12 1992-09-13 Yasutaka Igari Composition for sustained-release of erythropoietin
US5817471A (en) 1991-03-14 1998-10-06 The United States Of America As Represented By The Department Of Health And Human Services Trk tyrosine kinase receptor is the physiological receptor for nerve growth factor
CA2064331C (en) 1991-03-28 2003-02-18 Marvin L. Bayne Vascular endothelial cell growth factor c subunit
US5374617A (en) 1992-05-13 1994-12-20 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with FVIIa
ES2223040T3 (es) 1991-04-10 2005-02-16 The Scripps Research Institute Bibliotecas de receptor heterodimerilo que usan fagemidos.
EP0509841A3 (en) 1991-04-18 1993-08-18 Tonen Corporation Co-expression system of protein disulfide isomerase gene and useful polypeptide gene and process for producing the polypeptide using its system
CA2058820C (en) 1991-04-25 2003-07-15 Kotikanyad Sreekrishna Expression cassettes and vectors for the secretion of human serum albumin in pichia pastoris cells
JP3431140B2 (ja) 1991-04-26 2003-07-28 サーフィス・アクティブ・リミテッド 抗体およびその使用方法
US5330901A (en) 1991-04-26 1994-07-19 Research Corporation Technologies, Inc. Expression of human serum albumin in Pichia pastoris
US5646012A (en) * 1991-04-30 1997-07-08 Rhone-Poulenc Rorer S.A. Yeast promoter and use thereof
FR2676070B1 (fr) 1991-04-30 1994-09-30 Rhone Poulenc Rorer Sa Promoteur de levure et son utilisation.
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
US5304473A (en) * 1991-06-11 1994-04-19 Eli Lilly And Company A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
WO1992022324A1 (en) 1991-06-14 1992-12-23 Xoma Corporation Microbially-produced antibody fragments and their conjugates
FR2677996B1 (fr) 1991-06-21 1993-08-27 Rhone Poulenc Rorer Sa Vecteurs de clonage et/ou d'expression preparation et utilisation.
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
WO1993000109A1 (en) 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
US5223408A (en) * 1991-07-11 1993-06-29 Genentech, Inc. Method for making variant secreted proteins with altered properties
JPH05292972A (ja) 1991-07-29 1993-11-09 Tonen Corp 改良された酵母発現系
AU669484B2 (en) 1991-07-31 1996-06-13 Peri Development Applications (1985) Ltd Transgenic protein production
US5723719A (en) 1991-08-08 1998-03-03 Health Research Inc. Transgenic mouse as model for diseases involving dopaminergic dysfunction
DE4126968A1 (de) 1991-08-14 1993-02-18 Detlev Prof Dr Med Ganten Transgene ratten, die in ihrem genom mindestens ein menschliches gen enthalten, das an der blutdruckregulation beteiligt ist
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US6270989B1 (en) 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
PT101031B (pt) * 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
US5679777A (en) * 1991-11-08 1997-10-21 Somatogen, Inc. Hemoglobins as drug delivery agents
US5786883A (en) * 1991-11-12 1998-07-28 Pilkington Barnes Hind, Inc. Annular mask contact lenses
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US6348327B1 (en) * 1991-12-06 2002-02-19 Genentech, Inc. Non-endocrine animal host cells capable of expressing variant proinsulin and processing the same to form active, mature insulin and methods of culturing such cells
US5540923A (en) * 1991-12-06 1996-07-30 Landsforeningen Til Kraeftens Bekaemplse Interferon proteins
US5428139A (en) 1991-12-10 1995-06-27 The Dow Chemical Company Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals
ES2204899T3 (es) 1992-01-07 2004-05-01 Elan Pharmaceuticals, Inc. Modelos de animales transgenicos para la enfermedad de alzheimer.
GB9200417D0 (en) 1992-01-09 1992-02-26 Bagshawe Kenneth D Cytotoxic drug therapy
FR2686620B1 (fr) * 1992-01-27 1995-06-23 Rhone Poulenc Rorer Sa Serum-albumine humaine, preparation et utilisation.
FR2686900B1 (fr) 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
EP1514934B1 (en) 1992-02-06 2008-12-31 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
EP1306095A3 (en) 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5230886A (en) 1992-03-18 1993-07-27 Trustees Of Boston University Tumor cell suppression
DK36492D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Praeparat
USRE37302E1 (en) 1992-03-19 2001-07-31 Novo Nordisk A/S Peptide
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5460954A (en) 1992-04-01 1995-10-24 Cheil Foods & Chemicals, Inc. Production of human proinsulin using a novel vector system
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
DE69325777T2 (de) 1992-06-09 2000-03-09 Hoppe Ag Riegel und türschloss
CA2138161C (en) 1992-06-15 2003-10-21 Glenn C. Andrews Glucagon-like peptide and insulinotropin derivatives
US5686268A (en) * 1992-06-19 1997-11-11 Pfizer Inc. Fused proteins
US5505931A (en) 1993-03-04 1996-04-09 The Dow Chemical Company Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
JP3269504B2 (ja) 1992-07-08 2002-03-25 三菱ウェルファーマ株式会社 ヒト血清アルブミンの製造方法
FR2694294B1 (fr) * 1992-07-30 1994-09-09 Rhone Poulenc Rorer Sa Promoteur de levure et son utilisateur.
NZ255158A (en) 1992-07-31 1997-09-22 Genentech Inc Human growth hormone; stable pharmaceutically acceptable aqueous formulation and means for preparing and storing it
US5602307A (en) 1992-08-12 1997-02-11 Baylor College Of Medicine Non-human animal having predefined allele of a cellular adhesion gene
DE4244915C2 (de) * 1992-08-14 1998-12-03 Widmar Prof Dr Tanner DNA-Moleküle codierend Proteine, die an der O-Glykosylierung von Proteinen beteiligt sind
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5728553A (en) * 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US5731490A (en) 1992-09-29 1998-03-24 The Ontario Cancer Institute Mutant mouse lacking the expression of interferon regulatory factor 1 (IRF-1)
AU5171293A (en) * 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5441050A (en) 1992-12-18 1995-08-15 Neoprobe Corporation Radiation responsive surgical instrument
US6221958B1 (en) * 1993-01-06 2001-04-24 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5489743A (en) 1993-01-19 1996-02-06 Amgen Inc. Transgenic animal models for thrombocytopenia
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
FR2701953B1 (fr) 1993-02-22 1995-05-24 Centre Nat Rech Scient Protéine de fusion multi-VIP et procédé de préparation de VIP recombinant.
US5441734A (en) 1993-02-25 1995-08-15 Schering Corporation Metal-interferon-alpha crystals
US5780021A (en) 1993-03-05 1998-07-14 Georgetown University Method for treating type 1 diabetes using α-interferon and/or β-i
US5869445A (en) * 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
HU225496B1 (en) 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
AU6709794A (en) 1993-04-21 1994-11-08 Brigham And Women's Hospital Erythropoietin muteins with enhanced activity
GB9308581D0 (en) 1993-04-26 1993-06-09 Univ Manitoba A method for induction of antigen-specific suppression of immune-response
PT699075E (pt) * 1993-05-21 2002-05-31 Novo Nordisk As Factor vii modificado para inibicao de restenose vascular e de deposicao de plaquetas
JP3626187B2 (ja) 1993-06-07 2005-03-02 バイカル インコーポレイテッド 遺伝子治療に適するプラスミド
US5621039A (en) * 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
DK82893D0 (da) * 1993-07-08 1993-07-08 Novo Nordisk As Peptid
US5512459A (en) 1993-07-20 1996-04-30 Bionebraska, Inc. Enzymatic method for modification or recombinant polypeptides
EP0726772B1 (en) 1993-08-09 2001-11-07 Edward Baral A method for sensitization of cancer cells for killer cell mediated lysis
ZA946122B (en) 1993-08-17 1995-03-20 Amgen Inc Erythropoietin analogs
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
WO1995005848A1 (en) 1993-08-24 1995-03-02 Novo Nordisk A/S Protracted glp-1
US5521086A (en) * 1993-09-16 1996-05-28 Cephalon, Inc. Secretion sequence for the production of a heterologous protein in yeast
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5459031A (en) 1993-11-05 1995-10-17 Amgen Inc. Methods for controlling sialic acid derivatives in recombinant glycoproteins
EP0733070A1 (en) 1993-12-08 1996-09-25 Genzyme Corporation Process for generating specific antibodies
EP0658568A1 (en) 1993-12-09 1995-06-21 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
AU1272295A (en) 1993-12-17 1995-07-03 Novo Nordisk A/S Proinsulin-like compounds
DK144093D0 (h) 1993-12-23 1993-12-23 Novo Nordisk As
PT744958E (pt) 1994-01-31 2003-11-28 Univ Boston Bancos de anticorpos policlonais
US5550214A (en) 1994-02-10 1996-08-27 Brigham And Women's Hospital Isolated antigenic oncogene peptide fragments and uses
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5932780A (en) 1994-02-28 1999-08-03 Yissum Research Development Company Of Hebrew University Of Jerusalem Transgenic non-human animal assay system for anti-cholinesterase substances
GB9404270D0 (en) 1994-03-05 1994-04-20 Delta Biotechnology Ltd Yeast strains and modified albumins
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US5652352A (en) 1994-03-31 1997-07-29 Amgen Inc. Afamin: a human serum albumin-like gene
US5629286A (en) * 1994-03-31 1997-05-13 Brewitt; Barbara Homeopathic dilutions of growth factors
US5646113A (en) 1994-04-07 1997-07-08 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
FR2719593B1 (fr) 1994-05-06 1996-05-31 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur préparation et composition pharmaceutique les contenant.
GB9409496D0 (en) 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
GB9411356D0 (en) 1994-06-07 1994-07-27 Delta Biotechnology Ltd Yeast strains
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5985660A (en) 1994-06-15 1999-11-16 Systemix, Inc. Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation
US5639642A (en) * 1994-06-16 1997-06-17 Novo Nordisk A/S Synthetic leader peptide sequences
US5623054A (en) 1994-06-23 1997-04-22 The General Hospital Corporation Crucifer AFT proteins and uses thereof
WO1996003144A1 (en) 1994-07-27 1996-02-08 The Council Of The Queensland Institute Of Medical Research Polyepitope vaccines
JPH0851982A (ja) 1994-08-11 1996-02-27 Asahi Glass Co Ltd ヒト血清アルブミンをコードする改変された遺伝子
JPH0853500A (ja) 1994-08-11 1996-02-27 Asahi Glass Co Ltd 融合タンパク質および該タンパク質をコードする遺伝子
JPH0859509A (ja) 1994-08-16 1996-03-05 Teijin Ltd サイトメガロウイルス抗原血症治療剤およびサイトメガロウイルス感染症治療剤
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US6071923A (en) * 1994-09-16 2000-06-06 Bar-Ilan University Retinoyloxy aryl-substituted alkylene butyrates useful for the treatment of cancer and other proliferative diseases
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
FR2726576B1 (fr) 1994-11-07 1997-01-31 Pf Medicament Production de peptides analogues de peptides hydrophobes, peptide recombinant, sequence d'adn correspondante
FR2726471B1 (fr) 1994-11-07 1997-01-31 Pf Medicament Procede pour ameliorer l'immunogenicite d'un compose immunogene ou d'un haptene et application a la preparation de vaccins
KR100507431B1 (ko) 1994-11-07 2005-12-21 휴먼 게놈 사이언시즈, 인코포레이티드 종양괴사인자-γ
AT403167B (de) * 1994-11-14 1997-11-25 Immuno Ag Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems
US5695750A (en) 1994-11-25 1997-12-09 The United States Of America As Represented By The Secretary Of The Army Compositions for use to deactivate organophosphates
WO1996017941A2 (en) 1994-12-07 1996-06-13 Bionebraska, Inc. Production of c-terminal amidated peptides from recombinant protein constructs
AU700605B2 (en) 1994-12-07 1999-01-07 Bionebraska, Inc. Production of peptides using recombinant fusion protein constructs
JPH11501506A (ja) * 1994-12-12 1999-02-09 ベス イスラエル デアコネス メディカル センター キメラ型サイトカインおよびその利用
US20010006943A1 (en) 1994-12-23 2001-07-05 Ejvind Jensen Protracted GLP-1 compositions
DE69529998D1 (de) 1994-12-23 2003-04-24 Novo Nordisk As Glp-1 zusammensetzungen mit verlängerter wirkdauer
US5583415A (en) 1994-12-27 1996-12-10 Motorola, Inc. Apparatus for simulating high battery temperature for rechargeble battery systems
US5652224A (en) 1995-02-24 1997-07-29 The Trustees Of The University Of Pennsylvania Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism
US5928939A (en) 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
US5837281A (en) * 1995-03-17 1998-11-17 Takeda Chemical Industries, Ltd. Stabilized interface for iontophoresis
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
AU2363695A (en) 1995-04-27 1996-11-18 Human Genome Sciences, Inc. Human tumor necrosis factor receptors
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5480640A (en) 1995-05-02 1996-01-02 Schering Corporation Alpha interferon for treating prostate cancer
AU3134695A (en) 1995-05-05 1996-11-21 Human Genome Sciences, Inc. Human chemokine beta-8, chemokine beta-1 and macrophage infl ammatory protein-4
AU5724996A (en) 1995-05-05 1996-11-21 Eli Lilly And Company Single chain insulin with high bioactivity
US5728915A (en) 1995-05-08 1998-03-17 Children's Hospital, Inc. Transgenic mice which express simian SV 40 T-antigen under control of the retinoblastoma gene promoter
US5705151A (en) 1995-05-18 1998-01-06 National Jewish Center For Immunology & Respiratory Medicine Gene therapy for T cell regulation
US6001625A (en) 1995-05-19 1999-12-14 The United States Of America As Represented By The Secretary Of The Army Site-directed mutagenesis of esterases
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US5741815A (en) 1995-06-02 1998-04-21 Lai; Ching-San Methods for in vivo reduction of nitric oxide levels and compositions useful therefor
US5804162A (en) 1995-06-07 1998-09-08 Alliance Pharmaceutical Corp. Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
US5728707A (en) * 1995-07-21 1998-03-17 Constantia Gruppe Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5840542A (en) 1995-07-28 1998-11-24 Mogam Biotechnology Research Institute Method for manufacture of proinsulin with high export yield
DE19530865A1 (de) 1995-08-22 1997-02-27 Michael Dr Med Nauck Wirkstoff sowie Mittel zur parenteralen Ernährung
JPH0995455A (ja) 1995-09-29 1997-04-08 Sumitomo Pharmaceut Co Ltd 腎機能改善剤
US5766620A (en) * 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
US5849322A (en) 1995-10-23 1998-12-15 Theratech, Inc. Compositions and methods for buccal delivery of pharmaceutical agents
US5702717A (en) 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
DE69632062T2 (de) 1995-11-02 2004-11-18 Schering Corp. Kontinuierliche, niedrigdosierte zytokine-infusionstherapie
US6048964A (en) * 1995-12-12 2000-04-11 Stryker Corporation Compositions and therapeutic methods using morphogenic proteins and stimulatory factors
US6080409A (en) 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
GB9526733D0 (en) * 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US6087129A (en) 1996-01-19 2000-07-11 Betagene, Inc. Recombinant expression of proteins from secretory cell lines
WO1997026321A2 (en) 1996-01-19 1997-07-24 Board Of Regents, The University Of Texas System Recombinant expression of proteins from secretory cell lines
US6110707A (en) 1996-01-19 2000-08-29 Board Of Regents, The University Of Texas System Recombinant expression of proteins from secretory cell lines
US5767097A (en) * 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
US6150337A (en) 1996-01-23 2000-11-21 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by Ribavirin in activated T-lymphocytes
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US5616724A (en) 1996-02-21 1997-04-01 Cephalon, Inc. Fused pyrrolo[2,3-c]carbazole-6-ones
DE19639601A1 (de) 1996-02-28 1997-09-04 Bayer Ag Parapockenviren, die Fremd-DNA enthalten, ihre Herstellung und ihre Verwendung in Impfstoffen
US6045788A (en) * 1996-02-28 2000-04-04 Cornell Research Foundation, Inc. Method of stimulation of immune response with low doses of IL-2
US5912229A (en) * 1996-03-01 1999-06-15 Novo Nordisk Als Use of a pharmaceutical composition comprising an appetite-suppressing peptide
EP1231218B1 (en) 1996-03-01 2008-05-14 Novo Nordisk A/S An appetite-suppressing peptide, its compositions and use
JP3794748B2 (ja) * 1996-03-04 2006-07-12 第一アスビオファーマ株式会社 メタノール代謝系を有する微生物の培養法
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
EP0889949B1 (en) 1996-03-13 2003-05-28 Delta Biotechnology Limited Fermentation control
WO1997033899A1 (en) 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Apoptosis inducing molecule i
WO1997033998A1 (en) 1996-03-14 1997-09-18 The Immune Response Corporation Targeted delivery of genes encoding interferon
WO1997034997A1 (en) 1996-03-21 1997-09-25 Human Genome Sciences, Inc. Human endometrial specific steroid-binding factor i, ii and iii
EP0904278A4 (en) 1996-03-22 1999-09-15 Human Genome Sciences Inc MOLECULE II INDUCER OF APOPTOSIS
US6204022B1 (en) * 1996-04-12 2001-03-20 Pepgen Corporation And University Of Florida Low-toxicity human interferon-alpha analogs
WO1997039132A1 (en) 1996-04-16 1997-10-23 University Of Miami Stabilized preparations of human troponins and modifications thereof, diagnostic assay methods and assay kits
EP1854481B1 (en) * 1996-04-23 2014-07-16 Chugai Seiyaku Kabushiki Kaisha Cerebral stroke/cerebral edema preventive or remedy containing IL-8 binding inhibitor as active ingredient
ATE196844T1 (de) * 1996-05-22 2000-10-15 Protarga Inc Zusammensetzungen die konjugate von cis- docosahexaenoic-säure und taxotere enthalten
US5919815A (en) 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US6300065B1 (en) 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
WO1997047737A1 (de) * 1996-06-11 1997-12-18 Boehringer Mannheim Gmbh Rekombinante blutgerinnungsproteasen
US6110891A (en) 1996-06-21 2000-08-29 Alizyme Therapeutics Ltd. Lectin compositions and uses thereof
GB2318352A (en) 1996-06-25 1998-04-22 Dejan Markovic Polypeptides mimicking the activity of human erythropoietin
GB9613858D0 (en) 1996-07-02 1996-09-04 Cortecs Ltd Hydrophobic preparations
US5932547A (en) 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
US6110703A (en) 1996-07-05 2000-08-29 Novo Nordisk A/S Method for the production of polypeptides
US6828426B1 (en) 1996-07-15 2004-12-07 Chugai Seiyaku Kabushiki Kaisha VEGF-like factor
AR008077A1 (es) 1996-07-26 1999-12-09 Talarico Salinas Laura Beatriz Un polipeptido de fusion o una sal del mismo, su uso, un proceso para prepararlos, una composicion farmaceutica que los comprende, y un vector.
EP0918859A1 (en) 1996-08-02 1999-06-02 ZymoGenetics, Inc. Testis-specific insulin homolog polypeptides
US6190533B1 (en) 1996-08-15 2001-02-20 Exxon Chemical Patents Inc. Integrated hydrotreating steam cracking process for the production of olefins
ES2308787T3 (es) 1996-08-16 2008-12-01 Schering Corporation Antigenos de superficie de celular de mamiferos; reactivos relacionados.
JP2000516474A (ja) 1996-08-16 2000-12-12 ヒューマン ジノーム サイエンシーズ,インコーポレイテッド ヒトエンドカインα
EP1749836B1 (en) 1996-08-23 2009-06-17 Vegenics Limited Recombinant vascular endothelial cell growth factor D (VEGF-D)
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US5922761A (en) 1996-09-06 1999-07-13 Medinox, Inc. Methods for in vivo reduction of iron levels and compositions useful therefor
WO1998011136A1 (en) 1996-09-09 1998-03-19 Novo Nordisk A/S A cDNA AND PEPTIDE WITH RELATION TO CANCER AND WEIGHT LOSS
US20020052309A1 (en) 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury
AU7364696A (en) * 1996-09-18 1998-04-14 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like genes
US6225290B1 (en) 1996-09-19 2001-05-01 The Regents Of The University Of California Systemic gene therapy by intestinal cell transformation
US5994112A (en) 1996-10-09 1999-11-30 Incyte Pharmaceuticals, Inc. Human protein tyrosine kinase
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US5955508A (en) * 1996-10-15 1999-09-21 Loyola University Of Chicago Method for the enhancement of lymphocyte activity against opportunistic microbial pathogens
TR199901615T2 (en) 1996-10-18 1999-11-22 Genentech, Inc. Anti-ErbB2 antikorlar�.
WO1998017281A1 (en) 1996-10-24 1998-04-30 Vion Pharmaceuticals, Inc. MONOPHOSPHATE PRODRUGS OF β-L-FD4C AND β-L-FddC AS POTENT ANTIVIRAL AGENTS
EP0939804B2 (en) 1996-10-25 2011-06-15 Human Genome Sciences, Inc. NEUTROKINE alpha
JPH10134761A (ja) 1996-10-30 1998-05-22 Ebara Corp イオン注入装置及びイオン注入方法
US5908830A (en) * 1996-10-31 1999-06-01 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
EP1306092A3 (en) 1996-11-05 2003-05-07 Eli Lilly & Company Use of GLP-1 and analogs administered peripherally, in regulation of obesity
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
GB9623205D0 (en) * 1996-11-07 1997-01-08 Eurand Int Novel pharmaceutical compositions
ES2290799T3 (es) 1996-11-12 2008-02-16 Novo Nordisk A/S Uso de peptidos glp-1.
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6130248A (en) 1996-12-30 2000-10-10 Bar-Ilan University Tricarboxylic acid-containing oxyalkyl esters and uses thereof
US5833994A (en) 1997-01-08 1998-11-10 Paracelsian, Inc. Use of the AH receptor and AH receptor ligands to treat or prevent cytopathicity of viral infection
US6261801B1 (en) 1997-01-14 2001-07-17 Human Genome Sceineces, Inc. Nucleic acids encoding tumor necrosis factor receptor 5
AU5549998A (en) * 1997-01-24 1998-08-18 Novo Nordisk A/S Synthetic leader peptide sequences
PT1012274E (pt) 1997-01-28 2007-08-14 Craig A Rosen Receptor 4 contendo um domínio de morte (dm4; receptor de morte 4), membro da super-família do ftn e ligação a liart (ap02)
EP0921817B1 (en) 1997-01-29 2001-03-28 PolyMASC Pharmaceuticals plc Pegylation process
CA2280894A1 (en) 1997-02-13 1998-08-20 Applied Phytologics, Inc. Production of mature proteins in plants
GB2324529A (en) 1997-02-21 1998-10-28 Merck & Co Inc A combinatorial library based on a tetrapeptide substituted with aminomethylcoumarin for characterizing proteases
US7026447B2 (en) 1997-10-09 2006-04-11 Human Genome Sciences, Inc. 53 human secreted proteins
US6124495A (en) 1997-03-11 2000-09-26 Beacon Laboratories, Inc. Unsaturated oxyalkylene esters and uses thereof
US6110955A (en) 1997-03-11 2000-08-29 Beacon Laboratories, Inc. Metabolically stabilized oxyalkylene esters and uses thereof
US6030961A (en) * 1997-03-11 2000-02-29 Bar-Ilan Research & Development Co., Ltd. Oxyalkylene phosphate compounds and uses thereof
US5939455A (en) 1997-03-11 1999-08-17 Beacon Laboratories, Inc. Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
US6110970A (en) 1997-03-11 2000-08-29 Beacon Laboratories, Inc. Nitrogen-containing oxyalkylene esters and uses thereof
US5846774A (en) 1997-03-21 1998-12-08 Bionebraska, Inc. Chlorella virus promoters
JP2002510193A (ja) 1997-03-31 2002-04-02 イーライ・リリー・アンド・カンパニー グルカゴン様ペプチド−1類似体
WO1998046645A2 (en) 1997-04-14 1998-10-22 Micromet Gesellschaft Für Biomedizinische Forschung Mbh Method for the production of antihuman antigen receptors and uses thereof
TW577759B (en) 1997-04-18 2004-03-01 Ipsen Pharma Biotech Sustained release compositions in the form of microcapsules or implants and the process for their preparation
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU7273598A (en) 1997-05-05 1998-11-27 Regents Of The University Of California, The Naphthols useful in antiviral methods
US6214580B1 (en) 1997-05-30 2001-04-10 Human Genome Sciences, Inc. Human tumor necrosis factor receptor tr10
US6071743A (en) 1997-06-02 2000-06-06 Subsidiary No. 3, Inc. Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
WO1998056892A1 (en) 1997-06-11 1998-12-17 Human Genome Sciences, Inc. Human tumor necrosis factor receptor tr9
GB9713412D0 (en) 1997-06-26 1997-08-27 Delta Biotechnology Ltd Improved protein expression strains
US5858719A (en) 1997-07-17 1999-01-12 Incyte Pharmaceuticals, Inc. Polynucleotides encoding human ATP binding-cassette transport protein and methods of use
EP0902085B1 (en) 1997-09-01 2003-12-03 Aventis Pharma Deutschland GmbH Recombinant human erythropoietin with advantageous glycosylation profile
HUP9701554D0 (en) 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
US6472373B1 (en) 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
ES2186660T3 (es) 1997-09-21 2003-05-16 Schering Corp Terapia de combinacion para erradicar hcv-rna detectable en pacientes con infeccion por hepatitis c cronica.
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
EP1017413B2 (de) 1997-09-23 2007-11-07 Rentschler Biotechnologie GmbH Flüssige interferon-beta-formulierungen
US6117949A (en) 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6201072B1 (en) * 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6004573A (en) 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
CA2305690A1 (en) * 1997-10-09 1999-04-22 Human Genome Sciences, Inc. 53 human secreted proteins
JP4441112B2 (ja) 1997-11-03 2010-03-31 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド 新脈管形成および腫瘍増殖のインヒビターであるvegi
CA2309810C (en) 1997-12-03 2014-07-08 Roche Diagnostics Gmbh Erythropoietin with high specific activity
EP1049486A4 (en) 1997-12-05 2006-01-04 Lilly Co Eli GLP-1 FORMULATIONS
EP1039890B1 (en) * 1997-12-08 2004-03-17 Bristol-Myers Squibb Company Novel salts of metformin and method
DE69824039T2 (de) 1997-12-08 2005-08-18 Lexigen Pharmaceuticals Corp., Lexington Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
KR100253916B1 (ko) 1997-12-29 2000-05-01 김충환 사람 인슐린 전구체의 제조방법
US5951996A (en) 1998-02-04 1999-09-14 Czeizler Zaharia; Veronica L. Treatment of chronic diffuse GI bleeding with erythropoietin
US6017545A (en) * 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
US6221378B1 (en) * 1998-02-10 2001-04-24 Generex Pharmaceuticals Incorporated Mixed micellar delivery system and method of preparation
CA2320371C (en) 1998-02-13 2012-01-17 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and glp-1
EP1060191B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S Derivatives of glp-1 analogs
WO1999047160A1 (en) 1998-03-13 1999-09-23 Novo Nordisk A/S Stabilized aqueous peptide solutions
WO1999047161A1 (en) 1998-03-19 1999-09-23 Bionebraska, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
DE19813802A1 (de) 1998-03-27 1999-11-11 Retro Tech Gmbh Anti-virale Wirkung von Propolis durch Inhibition viraler Nukleinsäure Polymerasen
GB9806631D0 (en) 1998-03-28 1998-05-27 Safeglass Europ Limited Safetyglass
WO1999053064A2 (en) 1998-04-13 1999-10-21 Modex Therapeutiques, S.A. Methods of delivering glp-1
CA2270320A1 (en) 1998-04-28 1999-10-28 Patricia Lee Brubaker Novel microsphere composition
US6251868B1 (en) 1998-04-30 2001-06-26 Teijin Limited Method for treating a human immunodeficiency virus infection
CN1119352C (zh) 1998-05-15 2003-08-27 中国科学院上海生物化学研究所 人血清白蛋白在毕赤酵母中的表达与纯化
KR100694345B1 (ko) 1998-05-15 2007-03-12 쉐링 코포레이션 리바비린 및 인터페론 알파를 포함하는, 만성 c형 간염에 걸린 항-바이러스 치료에 대한 나이브 환자의 치료용 약제학적 조성물
US5970300A (en) * 1998-06-01 1999-10-19 Xerox Corporation Apparatus for applying scents to paper in a printer/copier
SE9802080D0 (sv) 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
EA004538B1 (ru) 1998-06-12 2004-06-24 Амилин Фармасьютикалс, Инк. ГЛЮКАГОНОПОДОБНЫЙ ПЕПТИД-1, УЛУЧШАЮЩИЙ ОТВЕТ β-КЛЕТОК НА ГЛЮКОЗУ У СУБЪЕКТОВ С НАРУШЕНИЕМ ТОЛЕРАНТНОСТИ К ГЛЮКОЗЕ
US6548653B1 (en) 1998-06-15 2003-04-15 Genzyme Transgenics Corporation Erythropoietin analog-human serum albumin fusion
CN1105727C (zh) 1998-06-17 2003-04-16 上海海济医药生物工程有限公司 重组人血清白蛋白的生产方法
JP2002518452A (ja) 1998-06-24 2002-06-25 エモリ ユニバーシティ Hivの治療薬物の製造のための他の抗hiv薬と組み合わせた3’−アジド−2’,3’−ジデオキシウリジンの使用
ES2273501T3 (es) 1998-06-30 2007-05-01 Novo Nordisk A/S Cristales de germinacion para la preparacion de peptidos o proteinas.
AU8508398A (en) 1998-07-15 2000-02-07 Wisconsin Alumni Research Foundation Treatment of diabetes with synthetic beta cells
DE69911975T2 (de) 1998-07-31 2004-09-09 Novo Nordisk A/S In-vitro stimulation von beta zellen vermehrung
GB9817084D0 (en) 1998-08-06 1998-10-07 Wood Christopher B A method for promoting extra-heptic production of proteins for the correction of hypoalbuminaemia,anaemia,thrombocytopenia and/or coagulation disorders
ES2335066T3 (es) 1998-08-10 2010-03-18 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Diferenciacion de celulas no productoras de insulina en celulas productoras de insulina glp-1 o exendina-4 y utilizaciones de las mismas.
US6346543B1 (en) * 1998-08-17 2002-02-12 Aventis Pharma S.A. Use of a taxoid to treat abnormal cell proliferation in the brain
CZ2001690A3 (cs) 1998-08-28 2002-04-17 Eli Lilly And Company Způsob podávání inzulinotropních peptidů
MY155270A (en) 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
US6193997B1 (en) * 1998-09-27 2001-02-27 Generex Pharmaceuticals Inc. Proteinic drug delivery system using membrane mimetics
US6290987B1 (en) 1998-09-27 2001-09-18 Generex Pharmaceuticals, Inc. Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids
US6429197B1 (en) 1998-10-08 2002-08-06 Bionebraska, Inc. Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
US6284725B1 (en) 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
EP1123306A4 (en) 1998-10-16 2002-07-03 Immunex Corp INHIBITORS OF BLOOD PLATE ACTIVATION AND GENERATION
CN1346369B (zh) 1998-10-23 2011-09-28 安姆根有限公司 用于预防和治疗贫血的方法以及组合物
ATE365210T1 (de) 1998-10-30 2007-07-15 Novozymes As Glykosylierte proteine mit reduzierter allergenität
WO2000032772A2 (en) 1998-11-30 2000-06-08 Eli Lilly And Company Erythropoietic compounds
US6048891A (en) * 1998-12-17 2000-04-11 Loma Linda University Medical Center Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease
US6294153B1 (en) 1998-12-21 2001-09-25 Generex Pharmaceuticals, Inc. Aerosol pharmaceutical formulation for pulmonary and nasal delivery
US6312665B1 (en) 1998-12-21 2001-11-06 Generex Pharmaceuticals Incorporated Aerosol formulations for buccal and pulmonary application
US6271200B1 (en) 1998-12-21 2001-08-07 Generex Pharmaceuticals Inc. Proteinic drug delivery system using aerosolized membrane-mimetic amphiphiles
WO2000037098A1 (en) 1998-12-22 2000-06-29 Eli Lilly And Company Shelf-stable formulation of glucagon-like peptide-1
GB9902000D0 (en) 1999-01-30 1999-03-17 Delta Biotechnology Ltd Process
US7465785B2 (en) * 1999-03-08 2008-12-16 Genentech, Inc. Polypeptide encoded by a nucleic acid over-expressed in melanoma
AU4451300A (en) 1999-04-09 2000-11-14 Human Genome Sciences, Inc. 48 human secreted proteins
AU3957400A (en) 1999-04-16 2000-11-02 Novo Nordisk A/S Dry, mouldable drug formulation
US6287588B1 (en) 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
US6348192B1 (en) * 1999-05-11 2002-02-19 Bayer Corporation Interleukin-2 mutein expressed from mammalian cells
DE19921537A1 (de) 1999-05-11 2000-11-23 Dieter Hoersch Verfahren zur Induzierung von Zellwachstum durch Verwendung geeigneter Mittel
PT1180121E (pt) 1999-05-17 2004-03-31 Conjuchem Inc Peptidos insulinotropicos de longa duracao
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
BR0010725A (pt) 1999-05-19 2002-02-19 Lexigen Pharm Corp Expressão e exportação de proteìnas de interferon-alfa como proteìnas de fusão de fc
US6344180B1 (en) 1999-06-15 2002-02-05 Bionebraska, Inc. GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
ATE372782T1 (de) 1999-06-21 2007-09-15 Lilly Co Eli Synergitische verwendung von thiazolidinedionen und glucagon-ähnlichem peptid-1 und dessen agonisten für die behandlung von nicht-insulin- abhängigen diabetes
JO2291B1 (en) * 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
WO2001005826A2 (en) 1999-07-19 2001-01-25 Gpc Biotech Inc. Chimeric polypeptides of serum albumin and uses related thereto
US20020048571A1 (en) 1999-07-19 2002-04-25 Jeno Gyuris Chimeric polypeptides of serum albumin and uses related thereto
EP1203005A4 (en) 1999-08-17 2004-11-24 Human Genome Sciences Inc 25 HUMAN SECRETED PROTEINS
US7144574B2 (en) * 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
TW200528436A (en) 1999-09-22 2005-09-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
CA2388432A1 (en) 1999-10-21 2001-04-26 Monsanto Company Post-translational modification of recombinant proteins produced in plants
WO2001030320A1 (en) 1999-10-22 2001-05-03 Amgen Inc. Biodegradable microparticles with novel erythropoietin stimulating protein
ATE381343T1 (de) 1999-11-03 2008-01-15 Novo Nordisk As Verwendung eines wachstumshormons oder eines wachstumshormon-sekretion fördernden mittels zur appetit-unterdrückung bzw. sättigungsinduktion
CA2324801A1 (en) 1999-11-10 2001-05-10 Andrew Gordon Swick Use of apo b secretion/mtp inhibitors and anti-obesity agents
US6569832B1 (en) * 1999-11-12 2003-05-27 Novo Nordisk A/S Inhibition of beta cell degeneration
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
JP2003523323A (ja) 1999-12-06 2003-08-05 ザ ジェネラル ホスピタル コーポレーション 膵臓幹細胞および移植におけるその使用
US20020025306A1 (en) 2000-01-07 2002-02-28 Baetge Edward E. Methods of increasing the glucose responsiveness of pancreatic ss-cells
EP1125579A3 (en) 2000-01-18 2003-01-02 Pfizer Products Inc. Uses of agrp-melanocortin receptor binding modulating compounds
WO2001055213A2 (en) 2000-01-27 2001-08-02 Eli Lilly And Company Process for solubilizing glucagon-like peptide 1 (glp-1) compounds
WO2001057084A1 (en) 2000-01-31 2001-08-09 Novo Nordisk A/S Crystallisation of a glp-1 analogue
CA2402733A1 (en) 2000-03-14 2001-09-20 Burkhard Goke Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
US20050100991A1 (en) 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
EP2213743A1 (en) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
MXPA02010333A (es) 2000-04-21 2003-04-25 Amgen Inc Metodos y composiciones para la prefencion y tratamiento de anemia.
IL142707A0 (en) 2000-04-27 2002-03-10 Pfizer Prod Inc Methods of treating obesity using a neurotensin receptor ligand
CN1309416C (zh) * 2000-05-15 2007-04-11 霍夫曼-拉罗奇有限公司 新的药物组合物
US20020061838A1 (en) 2000-05-17 2002-05-23 Barton Holmquist Peptide pharmaceutical formulations
DK1294757T3 (da) 2000-06-16 2007-03-19 Lilly Co Eli Glucagonlignende peptid 1-analoger
US6770620B2 (en) 2000-09-18 2004-08-03 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
US7101561B2 (en) * 2000-12-01 2006-09-05 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
WO2002045712A1 (en) 2000-12-04 2002-06-13 Biovitrum Ab Novel method and use
CN1483041A (zh) * 2000-12-07 2004-03-17 Glp-1融合蛋白
AU2002228608A1 (en) 2000-12-13 2002-06-24 Eli Lilly And Company Amidated glucagon-like peptide-1
WO2002047716A2 (en) 2000-12-13 2002-06-20 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
US7070973B2 (en) 2000-12-26 2006-07-04 Board Of Regents Of The University Of Nebraska Butyrylcholinesterase variants and methods of use
WO2002066062A2 (en) 2001-02-01 2002-08-29 Drucker Daniel J Enhancement of glp-2 activity
KR100399337B1 (ko) 2001-02-07 2003-09-26 드림바이오젠 주식회사 단백질의 무세포 번역후수식법
JP2004518756A (ja) 2001-03-07 2004-06-24 ノボ ノルディスク アクティーゼルスカブ Glp−1類似体およびpparリガンドの誘導体の組み合わせ使用
US20020169128A1 (en) 2001-04-09 2002-11-14 Geroge Sigounas Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
US20060084794A1 (en) 2001-04-12 2006-04-20 Human Genome Sciences, Inc. Albumin fusion proteins
US20050054051A1 (en) 2001-04-12 2005-03-10 Human Genome Sciences, Inc. Albumin fusion proteins
US20050244931A1 (en) 2001-04-12 2005-11-03 Human Genome Sciences, Inc. Albumin fusion proteins
WO2002085406A1 (en) 2001-04-24 2002-10-31 Restoragen, Inc. Methods and compositions for treating conditions associated with insulin resistance
US20030143191A1 (en) 2001-05-25 2003-07-31 Adam Bell Chemokine beta-1 fusion proteins
AU2002308706A1 (en) 2001-06-01 2002-12-16 Eli Lilly And Company Glp-1 formulations with protracted time action
ES2275889T3 (es) 2001-06-20 2007-06-16 Merck Sante Utilizacion de agentes antidiabeticos para fabricar un medicamento que tiene un efecto cicatrizante.
JP5562510B2 (ja) 2001-06-28 2014-07-30 ノヴォ ノルディスク アー/エス 修飾glp−1の安定な処方剤
ATE408414T1 (de) 2001-07-31 2008-10-15 Us Gov Health & Human Serv Glp 1 exendin 4 peptidanaloga und deren verwendungen
AU2002327430A1 (en) 2001-08-08 2003-02-24 Genzyme Corporation Methods for treating diabetes and other blood sugar disorders
EP1423136A4 (en) 2001-08-10 2007-07-25 Epix Pharm Inc POLYPEPTIDE CONJUGATES HAVING INCREASED CIRCULATION HALF-VIES
HUP0501192A3 (en) 2001-08-23 2006-06-28 Lilly Co Eli Glucagon-like peptide-1 analogs
AU2002332041A1 (en) 2001-10-05 2003-04-22 Human Genome Sciences, Inc. Albumin fusion proteins
EP2292273A3 (en) 2001-10-10 2011-11-23 BioGeneriX AG Remodeling and glycoconjugation of peptides
WO2003054182A2 (en) 2001-12-21 2003-07-03 Nexia Biotechnologies, Inc. Production of butyrylcholinesterases in transgenic mammals
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
KR101271635B1 (ko) 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
US20080167238A1 (en) 2001-12-21 2008-07-10 Human Genome Sciences, Inc. Albumin Fusion Proteins
EP1463752A4 (en) 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
US20080108560A1 (en) 2002-03-05 2008-05-08 Eli Lilly And Company Heterologous G-Csf Fusion Proteins
DE60336555D1 (de) * 2002-06-21 2011-05-12 Novo Nordisk Healthcare Ag Pegylierte glykoformen von faktor vii
CN1241946C (zh) * 2002-07-01 2006-02-15 美国福源集团 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
US6913890B2 (en) * 2002-12-18 2005-07-05 Palo Alto Research Center Incorporated Process for preparing albumin protein conjugated oligonucleotide probes
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
ES2380759T3 (es) * 2003-02-27 2012-05-18 Baxter International Inc. Método para la inactivación certificable de patógenos por irradiación en un fluido biológico
HRP20110714T1 (hr) 2003-06-12 2011-11-30 Eli Lilly And Company Fuzijski proteini analoga glp-1
BRPI0507026A (pt) 2004-02-09 2007-04-17 Human Genome Sciences Inc proteìnas de fusão de albumina
US20060051859A1 (en) 2004-09-09 2006-03-09 Yan Fu Long acting human interferon analogs
US7436410B2 (en) * 2005-04-01 2008-10-14 Seiko Epson Corporation System and method for programming a controller
EP1924596A4 (en) 2005-08-12 2009-07-29 Human Genome Sciences Inc ALBUM INFUSION PROTEINS
US7438904B1 (en) 2005-10-04 2008-10-21 University Of Kentucky Research Foundation High-activity mutants of butyrylcholinesterase for cocaine hydrolysis and method of generating the same
CA2562249A1 (en) 2005-10-20 2007-04-20 University Of Ottawa Heart Institute Anf analogue
EP1816201A1 (en) * 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
US8334365B2 (en) 2006-06-07 2012-12-18 Human Genome Sciences, Inc. Albumin fusion proteins
PT2717898T (pt) * 2011-06-10 2019-05-20 Bioverativ Therapeutics Inc Compostos pró-coagulantes e processos para a sua utilização

Also Published As

Publication number Publication date
EP2267026A1 (en) 2010-12-29
US20140010798A1 (en) 2014-01-09
EP1276856A1 (en) 2003-01-22
EP2236152B1 (en) 2014-06-04
US9775888B2 (en) 2017-10-03
CA2405550A1 (en) 2001-10-25
US7785599B2 (en) 2010-08-31
WO2001079442A2 (en) 2001-10-25
WO2001079480A1 (en) 2001-10-25
ES2529300T3 (es) 2015-02-18
US6994857B2 (en) 2006-02-07
US20050266533A1 (en) 2005-12-01
EP2067488A1 (en) 2009-06-10
EP1274719A2 (en) 2003-01-15
EP1278544A4 (en) 2004-08-18
EP1832599A2 (en) 2007-09-12
CA2405525A1 (en) 2001-10-25
US20100189686A1 (en) 2010-07-29
CA2405563A1 (en) 2001-10-25
WO2001079480A9 (en) 2003-09-18
WO2001079258A9 (en) 2002-02-28
EP2275557A1 (en) 2011-01-19
WO2001079444A3 (en) 2002-05-23
JP2003531590A (ja) 2003-10-28
JP2003530846A (ja) 2003-10-21
FR16C0043I1 (h) 2016-12-09
US6905688B2 (en) 2005-06-14
EP1278767A4 (en) 2003-11-12
AU2001264563A1 (en) 2001-10-30
EP1278544A2 (en) 2003-01-29
JP2003530847A (ja) 2003-10-21
WO2001079442A3 (en) 2002-06-06
EP1832599A3 (en) 2007-11-21
AU2001262942A1 (en) 2001-10-30
WO2001079258A1 (en) 2001-10-25
CA2405557A1 (en) 2001-10-25
AU2001261024A1 (en) 2001-10-30
AU2001259063A1 (en) 2001-10-30
EP1276849A2 (en) 2003-01-22
EP2357008A1 (en) 2011-08-17
US7507414B2 (en) 2009-03-24
AU2001259066A1 (en) 2001-10-30
US20030199043A1 (en) 2003-10-23
EP2236152A1 (en) 2010-10-06
US6926898B2 (en) 2005-08-09
EP1278767A1 (en) 2003-01-29
EP2298355A3 (en) 2011-06-29
FR16C0043I2 (fr) 2020-04-10
US20040010134A1 (en) 2004-01-15
WO2001079444A2 (en) 2001-10-25
US20140004095A1 (en) 2014-01-02
US9821039B2 (en) 2017-11-21
EP1274720A1 (en) 2003-01-15
US20120141449A1 (en) 2012-06-07
EP2311872A1 (en) 2011-04-20
EP2213743A1 (en) 2010-08-04
CA2405912A1 (en) 2001-10-18
WO2001079271A9 (en) 2002-02-28
EP1803730A1 (en) 2007-07-04
US20030171267A1 (en) 2003-09-11
CA2405701A1 (en) 2001-10-25
EP2298355A2 (en) 2011-03-23
EP1276756A4 (en) 2004-06-09
US20070287173A9 (en) 2007-12-13
US20130266553A1 (en) 2013-10-10
JP2003530852A (ja) 2003-10-21
WO2001077137A1 (en) 2001-10-18
JP2003530838A (ja) 2003-10-21
CA2405709A1 (en) 2001-10-25
WO2001079443A3 (en) 2002-02-21
WO2001079443A2 (en) 2001-10-25
EP1983055A1 (en) 2008-10-22
US10080785B2 (en) 2018-09-25
EP2206720A1 (en) 2010-07-14
CA2405557C (en) 2013-09-24
US20030219875A1 (en) 2003-11-27
JP2004506407A (ja) 2004-03-04
US20080261877A1 (en) 2008-10-23
US7482013B2 (en) 2009-01-27
US8946156B2 (en) 2015-02-03
AU2001274809A1 (en) 2001-10-30
AU2001266557A1 (en) 2001-10-23
US20180200346A1 (en) 2018-07-19
JP2003530839A (ja) 2003-10-21
US20040171123A1 (en) 2004-09-02
EP1274720A4 (en) 2004-08-18
EP2216409B1 (en) 2014-12-03
JP2011217750A (ja) 2011-11-04
US20110280830A9 (en) 2011-11-17
US20080269127A1 (en) 2008-10-30
US20080267962A1 (en) 2008-10-30
US9849162B2 (en) 2017-12-26
EP2295456A1 (en) 2011-03-16
EP1276849A4 (en) 2004-06-09
US20120252732A1 (en) 2012-10-04
WO2001077137A9 (en) 2002-05-02
WO2001079271A1 (en) 2001-10-25
US20080269125A1 (en) 2008-10-30
ES2484966T3 (es) 2014-08-12
EP1276856A4 (en) 2004-06-09
US20120141415A1 (en) 2012-06-07
EP1276756A1 (en) 2003-01-22
EP1274719A4 (en) 2004-05-19
US20050266532A1 (en) 2005-12-01
US20080269128A1 (en) 2008-10-30
US20080131399A1 (en) 2008-06-05
US20090285816A9 (en) 2009-11-19
US20030125247A1 (en) 2003-07-03
US20080269126A1 (en) 2008-10-30
CA2747325A1 (en) 2001-10-25
DK2236152T3 (da) 2014-07-07
JP2014057589A (ja) 2014-04-03
EP2216409A1 (en) 2010-08-11
DK2216409T3 (en) 2015-01-05

Similar Documents

Publication Publication Date Title
BE2016C059I2 (h)
JP2000347946A5 (h)
JP2003526978A5 (h)
JP2003510788A5 (h)
JP2001084274A5 (h)
JP2003527891A5 (h)
JP2001324678A5 (h)
JP2001339853A5 (h)
JP2001305432A5 (h)
JP2002006528A5 (h)
JP2002144601A5 (h)
JP2002048400A5 (h)
JP2002018074A5 (h)
JP2002140082A5 (h)
JP2002104386A5 (h)
HU0004973D0 (h)
JP2002183336A5 (h)
FR2786751A3 (h)
CN3142146S (h)
CN3139851S (h)
CN3144584S (h)
CN3143796S (h)
CN3143422S (h)
CN3143240S (h)
CN3142120S (h)